var title_f12_43_12976="Adult proximal fibular fracture";
var content_f12_43_12976=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79694%7ERHEUM%2F55491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79694%7ERHEUM%2F55491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proximal fibula fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This set of anteroposterior and lateral radiographs of the knee and lower leg shows a transverse fracture of the proximal fibula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl B Fields, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distal fibula fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 217px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior radiograph shows a fracture of the distal fibula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl B Fields, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_43_12976=[""].join("\n");
var outline_f12_43_12976=null;
var title_f12_43_12977="CRPS dystrophic skin";
var content_f12_43_12977=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dystrophic skin changes in complex regional pain syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: David D Sherry, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_43_12977=[""].join("\n");
var outline_f12_43_12977=null;
var title_f12_43_12978="Radiofrequency vein ablation PI";
var content_f12_43_12978=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F87609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F87609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Radiofrequency vein ablation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 652px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During radiofrequency vein ablation, the doctor inserts a special wire into the diseased vein. The wire heats up the vein from the inside and seals it closed. Laser vein ablation works in a very similar way.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_43_12978=[""].join("\n");
var outline_f12_43_12978=null;
var title_f12_43_12979="Sodium acetate: Drug information";
var content_f12_43_12979=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium acetate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/16/13571?source=see_link\">",
"    see \"Sodium acetate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/55/883?source=see_link\">",
"    see \"Sodium acetate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F221569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Electrolyte Supplement, Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F221563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Sodium acetate is metabolized to bicarbonate on an equimolar basis outside the liver; administer in large volume I.V. fluids as a sodium source. Refer to Sodium Bicarbonate monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maintenance electrolyte requirements of sodium in parenteral nutrition solutions:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daily requirements: 3-4 mEq/kg/24 hours or 25-40 mEq/1000 kcal/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum: 100-150 mEq/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2871758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/55/883?source=see_link\">",
"      see \"Sodium acetate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Maintenance electrolyte requirements of sodium in parenteral nutrition solutions:",
"     </b>",
"     I.V.: 3-4 mEq/kg/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F221564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as anhydrous [concentrate, preservative free]: 2 mEq/mL (20 mL, 50 mL, 100 mL); 4 mEq/mL (50 mL, 100 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F221556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Must be diluted prior to I.V. administration; infuse hypertonic solutions (&gt;154 mEq/L) via a central line; maximum rate of administration: 1 mEq/kg/hour",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F221574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with acids, acidic salts, alkaloid salts, calcium salts, catecholamines, atropine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Enalaprilat, esmolol, labetalol, nicardipine, ondansetron.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Cimetidine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F221555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium source in large volume I.V. fluids to prevent or correct hyponatremia in patients with restricted intake; used to counter acidosis through conversion to bicarbonate",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F221567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Thrombosis, hypervolemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Chemical cellulitis at injection site (extravasation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypernatremia, dilution of serum electrolytes, overhydration, hypokalemia, metabolic alkalosis, hypocalcemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Gastric distension, flatulence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Congestive conditions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F221558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypernatremia and fluid retention",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F221548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypernatremia: Close monitoring of serum sodium concentrations is needed to avoid hypernatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acid/base disorders: Use with caution in patients with acid/base alterations; contains acetate, monitor closely during acid/base correction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edema: Use with caution in edematous patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use extreme caution in patients with HF; monitor closely for edema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; monitor serum sodium concentrations closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aluminum: Solution for injection contains aluminum; use with caution in patients with impaired renal function and in premature infants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation: Avoid extravasation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13888238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Sodium requirements do not change during pregnancy (IOM, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13888239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium is found in breast milk. Sodium requirements do not change during lactation (IOM, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F221559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium acetate anhydrous (2 mEq/mL): 1 mL = 164 mg sodium acetate anhydrous = 2 mEq of sodium (46 mg) and acetate (118 mg)",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sodium Acetate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mEq/mL (20 mL): $1.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mEq/mL (50 mL): $5.45",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate",
"      </i>",
"      , Washington, DC: National Academy Press, 2004.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9926 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-DF5911362B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_43_12979=[""].join("\n");
var outline_f12_43_12979=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221569\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221563\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2871758\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221564\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221554\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221545\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221556\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221574\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221555\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221567\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221558\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221548\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300048\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222956\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221552\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13888238\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13888239\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221559\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323860\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9926\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9926|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/16/13571?source=related_link\">",
"      Sodium acetate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/55/883?source=related_link\">",
"      Sodium acetate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_43_12980="Ivermectin (systemic): Patient drug information";
var content_f12_43_12980=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ivermectin (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40613?source=see_link\">",
"     see \"Ivermectin (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/49/33557?source=see_link\">",
"     see \"Ivermectin (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13841863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Stromectol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13854410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat infections caused by worms.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13854409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ivermectin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13854414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13854415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13854417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13854412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F13854413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13854418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13854419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83354 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-30319E2B35-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_43_12980=[""].join("\n");
var outline_f12_43_12980=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13841863\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854410\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854409\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854414\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854415\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854417\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854412\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854413\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854418\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854419\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40613?source=related_link\">",
"      Ivermectin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/49/33557?source=related_link\">",
"      Ivermectin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/16/1283?source=related_link\">",
"      Ivermectin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/34/9764?source=related_link\">",
"      Ivermectin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/53/37714?source=related_link\">",
"      Ivermectin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_43_12981="Incidentally discovered sellar masses (pituitary incidentalomas)";
var content_f12_43_12981=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Incidentally discovered sellar masses (pituitary incidentalomas)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/43/12981/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/43/12981/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/43/12981/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/43/12981/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/43/12981/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/43/12981/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/43/12981/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequent detection of unsuspected anatomic abnormalities in many glands (\"incidentalomas\"), including the pituitary, made possible by the sensitivity of magnetic resonance imaging (MRI), raises the question of how to evaluate patients who have such an abnormality. The causes, evaluation, and treatment of pituitary incidentaloma are discussed here. The causes, clinical presentation, and evaluation of sellar masses are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link\">",
"     \"Causes, presentation, and evaluation of sellar masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;pituitary incidentaloma&rdquo; refers to a previously unsuspected lesion that is detected on an imaging study performed for reasons other than pituitary symptoms or disease. Among adults undergoing imaging studies (CT or MRI) for reasons other than pituitary symptoms or disease, the frequency of incidentally discovered signal abnormalities (&lt;10 mm) varies among studies from 4 to 20 percent by CT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/1-3\">",
"     1-3",
"    </a>",
"    ] and 10 to 38 percent by MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Not all incidentally discovered sellar masses are pituitary adenomas. In one study of 61 incidentally discovered sellar masses found among 1000 unselected autopsy specimens, there were 37 Rathke&rsquo;s cleft cysts, 18 pituitary adenomas, and two each of hyperplasia, infarction, and hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/6\">",
"     6",
"    </a>",
"    ]. However, pituitary adenomas are a common finding, as illustrated by a review of 29 autopsy studies that included over 18,000 pituitary glands [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/7\">",
"     7",
"    </a>",
"    ]. The frequency of pituitary adenomas was approximately 10 percent, and nearly all of the adenomas were microadenomas (&lt;10 mm). The frequencies were similar for men and women, and across age groups in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS OF REFERRED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are referred for evaluation of incidentally discovered MRI signal abnormalities within the sella tend to have larger lesions and a higher incidence of neurologic abnormalities than would be expected from autopsy and MRI series of unselected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This presumably reflects the selection process of a referral population. In one series of 31 referred patients, 16 had lesions 10 mm or larger [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/9\">",
"     9",
"    </a>",
"    ]. Three of the 31 had hormonal abnormalities; two had slightly high serum alpha-subunit concentrations, and two mild hyperprolactinemia (one patient had both). In the largest reported series of incidentally discovered sellar masses, 506 patients were reported from referral centers, in response to a questionnaire, to have incidentally-discovered sellar masses; the majority were &gt;10 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall frequency of different types of pituitary adenomas is not known because many large series of incidentally discovered sellar masses intentionally exclude those patients who have lesions that are hypersecreting. In our experience, however, it is common for a sellar mass to be discovered incidentally, but on further evaluation, the patient is found to have hormonal hypersecretion. Some of these patients even have obvious clinical manifestations of the hypersecretion (eg, acromegaly) that had been overlooked until the mass was discovered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little information is available about the natural history of incidentally discovered sellar masses. In the largest series of 506 patients described above, 258 underwent surgery soon after discovery of the mass, and 248 were followed for a mean of 26.9 months (range: 6 to 173) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/7\">",
"     7",
"    </a>",
"    ]. The size of the sellar mass increased, by MRI, in 30 (20 of the 123 with lesions originally &gt;10mm, and 10 of the 57 with lesions originally &lt;10mm). Among the latter, only three (all &ge;5 mm) increased to &gt;10 mm in 65 to 84 months of observation. In a report since that review, 2 of 16 with a mass &lt;10 mm increased in size in an average of 41 months of observation, neither to a clinically significant degree [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review and meta-analysis of studies that included 865 patients with incidentally discovered, nonfunctioning sellar masses, those &ge;10 mm were approximately four times more likely to experience growth during follow-up than those &lt;10 mm (incidence 12.5 versus 3.3 per 100 person-years, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of a patient found incidentally to have a lesion within the pituitary depends upon the size of the lesion (",
"    <a class=\"graphic graphic_algorithm graphicRef80461 \" href=\"UTD.htm?2/15/2302\">",
"     algorithm 1",
"    </a>",
"    ). Lesions 10 mm or larger are more likely to be associated with visual and hormonal abnormalities at the time they are discovered and are more likely to enlarge during observation than smaller lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22489?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lesions 10 mm or larger",
"    </span>",
"    &nbsp;&mdash;&nbsp;These lesions should be evaluated as a symptomatic sellar mass of similar size. Vision should be evaluated clinically and by formal testing of acuity and fields. We suggest that these patients undergo clinical and biochemical evaluation for both hormone hypersecretion and hypopituitarism. For hypersecretion, this includes serum prolactin, IGF-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/13\">",
"     13",
"    </a>",
"    ], LH, FSH, and alpha subunit, and 24-hour urine cortisol [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/14\">",
"     14",
"    </a>",
"    ]. The evaluation of hypopituitarism is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link&amp;anchor=H26#H26\">",
"     \"Causes, presentation, and evaluation of sellar masses\", section on 'Hormonal evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=see_link\">",
"     \"Diagnosis of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with pituitary adenomas resulting in hormonal hypersecretion (eg, hyperprolactinemia, acromegaly, or Cushing's disease) should be treated as other patients with these disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link\">",
"       \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7322?source=see_link\">",
"       \"Treatment of acromegaly\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17834?source=see_link\">",
"       \"Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with gonadotroph adenomas and other clinically nonfunctioning lesions causing visual impairment or other neurologic symptoms, transsphenoidal surgery is the treatment of choice for initial therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8857?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of gonadotroph and other clinically nonfunctioning adenomas\", section on 'Surgical approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with adenomas less than 20 mm without clinically important hormonal hypersecretion and no visual or other neurologic abnormalities, we suggest careful observation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/15\">",
"       15",
"      </a>",
"      ]. The patient should be monitored for size of the mass, visual changes, and hormonal hypersecretion in six and 12 months, then annually for several years, and perhaps less frequently thereafter. Hormonal hyposecretion should be treated by appropriate replacement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8857?source=see_link&amp;anchor=H7585601#H7585601\">",
"       \"Treatment of gonadotroph and other clinically nonfunctioning adenomas\", section on 'Asymptomatic adenomas'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28006?source=see_link\">",
"       \"Treatment of hypopituitarism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lesions less than 10 mm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with smaller lesions should be evaluated clinically for hormonal hypersecretion and biochemically for any hypersecretion suspected clinically. Only serum prolactin should be measured if there is no clinical suspicion of hormonal hypersecretion, an approach that, in one report, was much more cost effective than either measurement of multiple hormones or performance of follow-up MRIs at six and 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/16\">",
"     16",
"    </a>",
"    ]. No evaluation for hormonal hyposecretion or visual abnormalities is necessary. Our approach differs from the 2011 Endocrine Society Guidelines, which recommend that patients with an incidentaloma of any size undergo initial testing for hormonal hypersecretion and hypopituitarism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with lesions not associated with hormonal hypersecretion may be treated as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with lesions 2 to 4 mm in diameter, we suggest no further testing, as additional tests do not appear to affect outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12981/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients with lesions 5 to 9 mm in diameter, we suggest monitoring with pituitary MRI yearly for two years; if the lesion is stable in this period, the frequency can be decreased to every few years and then even less often.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3177503\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pituitary incidentaloma is a previously unsuspected sellar mass that is detected on an imaging study performed for reasons other than pituitary symptoms or disease.",
"     </li>",
"     <li>",
"      Pituitary incidentalomas are common. In imaging studies, the frequency of incidentally discovered pituitary lesions is 4 to 20 percent by CT scan and 10 to 38 percent by MRI. In autopsy studies, the frequency of previously unsuspected pituitary adenomas is approximately 10 percent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are referred for evaluation of incidentally discovered MRI abnormalities within the sella tend to have larger lesions and a higher incidence of neurologic abnormalities than would be expected from autopsy and MRI series of unselected patients. This presumably reflects the selection process of a referral population. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Characteristics of referred patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Incidentally discovered sellar masses &gt;10 mm in diameter are more likely to grow than those &lt;10 mm. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with pituitary incidentalomas &ge;10 mm:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest evaluation for hormonal hyper- and hyposecretion (hypopituitarism). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link&amp;anchor=H26#H26\">",
"       \"Causes, presentation, and evaluation of sellar masses\", section on 'Hormonal evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=see_link\">",
"       \"Diagnosis of hypopituitarism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with gonadotroph adenomas and other clinically nonfunctioning lesions causing visual impairment or other neurologic symptoms, we suggest transsphenoidal surgery for initial therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8857?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of gonadotroph and other clinically nonfunctioning adenomas\", section on 'Surgical approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with pituitary lesions &ge;10 mm and symptoms related to clinically important hormonal hypersecretion (hyperprolactinemia, Cushing&rsquo;s syndrome, acromegaly), treatment is described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link\">",
"       \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7322?source=see_link\">",
"       \"Treatment of acromegaly\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17834?source=see_link\">",
"       \"Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with pituitary lesions &ge;10 mm without neurologic symptoms or hormonal hypersecretion, we suggest close observation with hormonal testing (for both hyper- and hyposecretion), visual testing, and pituitary MRI at six and 12 months during the first year. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Lesions 10 mm or larger'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8857?source=see_link&amp;anchor=H7585601#H7585601\">",
"       \"Treatment of gonadotroph and other clinically nonfunctioning adenomas\", section on 'Asymptomatic adenomas'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with pituitary incidentalomas &lt;10 mm:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest that only serum prolactin be measured if there is no clinical suspicion of hormonal hypersecretion.",
"     </li>",
"     <li>",
"      For patients with lesions 2 to 4 mm in diameter, we suggest no further imaging tests.",
"     </li>",
"     <li>",
"      For those with lesions between 5 to 9 mm in diameter, we suggest MRI yearly for two years; if the lesion is stable in this period, the frequency can be decreased to every few years and then less often. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Lesions less than 10 mm'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/1\">",
"      Peyster RG, Adler LP, Viscarello RR, et al. CT of the normal pituitary gland. Neuroradiology 1986; 28:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/2\">",
"      Wolpert SM, Molitch ME, Goldman JA, Wood JB. Size, shape, and appearance of the normal female pituitary gland. AJR Am J Roentgenol 1984; 143:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/3\">",
"      Chambers EF, Turski PA, LaMasters D, Newton TH. Regions of low density in the contrast-enhanced pituitary gland: normal and pathologic processes. Radiology 1982; 144:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/4\">",
"      Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994; 120:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/5\">",
"      Chong BW, Kucharczyk W, Singer W, George S. Pituitary gland MR: a comparative study of healthy volunteers and patients with microadenomas. AJNR Am J Neuroradiol 1994; 15:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/6\">",
"      Teramoto A, Hirakawa K, Sanno N, Osamura Y. Incidental pituitary lesions in 1,000 unselected autopsy specimens. Radiology 1994; 193:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/7\">",
"      Molitch ME. Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am 2008; 37:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/8\">",
"      Reincke M, Allolio B, Saeger W, et al. The 'incidentaloma' of the pituitary gland. Is neurosurgery required? JAMA 1990; 263:2772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/9\">",
"      Donovan LE, Corenblum B. The natural history of the pituitary incidentaloma. Arch Intern Med 1995; 155:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/10\">",
"      Sanno N, Oyama K, Tahara S, et al. A survey of pituitary incidentaloma in Japan. Eur J Endocrinol 2003; 149:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/11\">",
"      Karavitaki N, Collison K, Halliday J, et al. What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol (Oxf) 2007; 67:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/12\">",
"      Fern&aacute;ndez-Balsells MM, Murad MH, Barwise A, et al. Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J Clin Endocrinol Metab 2011; 96:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/13\">",
"      Wade AN, Baccon J, Grady MS, et al. Clinically silent somatotroph adenomas are common. Eur J Endocrinol 2011; 165:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/14\">",
"      Karavitaki N, Ansorge O, Wass JA. Silent corticotroph adenomas. Arq Bras Endocrinol Metabol 2007; 51:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/15\">",
"      Dekkers OM, Hammer S, de Keizer RJ, et al. The natural course of non-functioning pituitary macroadenomas. Eur J Endocrinol 2007; 156:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/16\">",
"      King JT Jr, Justice AC, Aron DC. Management of incidental pituitary microadenomas: a cost-effectiveness analysis. J Clin Endocrinol Metab 1997; 82:3625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12981/abstract/17\">",
"      Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:894.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6642 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-BCBD45DDC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_43_12981=[""].join("\n");
var outline_f12_43_12981=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3177503\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CHARACTERISTICS OF REFERRED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lesions 10 mm or larger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lesions less than 10 mm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3177503\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/6642\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6642|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?2/15/2302\" title=\"algorithm 1\">",
"      Eval of pituitary incidentaloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=related_link\">",
"      Causes, presentation, and evaluation of sellar masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22489?source=related_link\">",
"      Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=related_link\">",
"      Diagnosis of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17834?source=related_link\">",
"      Primary therapy of Cushing's disease: Transsphenoidal surgery and pituitary irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7322?source=related_link\">",
"      Treatment of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8857?source=related_link\">",
"      Treatment of gonadotroph and other clinically nonfunctioning adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28006?source=related_link\">",
"      Treatment of hypopituitarism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_43_12982="AL amyloidosis bruising and ecchymoses";
var content_f12_43_12982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F69541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F69541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Easy bruising and ecchymoses of the skin in AL amyloidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 573px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_43_12982=[""].join("\n");
var outline_f12_43_12982=null;
var title_f12_43_12983="Mobilization of rectum";
var content_f12_43_12983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mobilization of the rectum and detachment from the posterior uterus during hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 462px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_43_12983=[""].join("\n");
var outline_f12_43_12983=null;
var title_f12_43_12984="Amikacin: Pediatric drug information";
var content_f12_43_12984=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amikacin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"    see \"Amikacin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/57/6036?source=see_link\">",
"    see \"Amikacin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amikacin Sulfate Injection, USP;",
"     </li>",
"     <li>",
"      Amikin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Aminoglycoside",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11431469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose not well-defined in premature infants; monitor closely. Dosage should be based on actual weight unless the patient has hydrops fetalis. Consider single-dose administration with serum concentration monitoring in patients with urine output &lt;1 mL/kg/hour or serum creatinine &gt;1.3 mg/dL rather than scheduled dosing. Consider prolongation of dosing interval when coadministered with ibuprofen or indomethacin or in neonates with history of the following: Birth depression, birth hypoxia/asphyxia, or cyanotic congenital heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General dosing; susceptible infection:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Age-directed dosing  (Allegaert, 2006; Allegaert, 2008; Labaune, 2001; Sherwin, 2009):",
"     <b>",
"      Note:",
"     </b>",
"     Postmenstrual age is the sum of gestational age (weeks) and postnatal age (weeks) (Engle, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     PMA &le;27 weeks: 15-20 mg/kg/dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     PMA 28-33 weeks: 15-20 mg/kg/dose every 36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     PMA &ge;34 weeks: 15 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weight-directed dosing (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Body weight &le;2 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     PNA &le;7 days: 15 mg/kg/dose every 48 hours; in neonates &lt;1 kg, the dosing interval may be extended through the first 2 weeks of life",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     PNA 8-28 days: 15 mg/kg/dose every 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Body weight &gt;2 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     PNA &le;7 days: 15 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     PNA 8-28 days: 15 mg/kg/dose every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Meningitis :",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Use smaller doses and longer intervals for neonates &lt;2 kg (Tunkel, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     PNA &le;7 days and &ge;2 kg: 15-20 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     PNA &gt;7 days and &ge;2 kg: 30 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 8 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"      see \"Amikacin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage should be based on an estimate of ideal body weight. In morbidly obese children, adolescents, and adults, dosage requirement may best be estimated using a dosing weight of IBW + 0.4 (TBW - IBW).  Dosage should be individualized based upon serum concentration monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      General dosing, severe, susceptible infections:",
"     </b>",
"     I.M., I.V.: 15-22.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 8 hours (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012); some consultants recommend initial doses of 30 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 8 hours in patients who may require larger doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      CNS infections:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Meningitis (Tunkel, 2004):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants and Children: I.V.: 20-30 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adolescents: I.V.: 15 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     VP-shunt infection, ventriculitis: Limited data available: Intraventricular/intrathecal",
"     <b>",
"      (use a preservative free preparation)",
"     </b>",
"     : 5-50 mg/",
"     <b>",
"      day",
"     </b>",
"     ; usual dose: 30 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cystic fibrosis, pulmonary infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Traditional dosing: I.V., I.M.: 10 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended-interval dosing: I.V.: 30 mg/kg/dose every 24 hours (Flume, 2009);",
"     <b>",
"      Note:",
"     </b>",
"     The CF Foundation recommends extended-interval dosing as preferred over traditional dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Intra-abdominal infection, complicated:",
"     </b>",
"     15-22.5 mg/kg/day divided every 8-24 hours (Solomkin, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Mycobacterial, nontuberculous infection (eg, MAC):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children: I.V.: 15-30 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 12-24 hours as part of a multiple drug regimen; maximum daily dose: 1500 mg/",
"     <b>",
"      day",
"     </b>",
"     (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: I.V.: 10-15 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     every 24 hours as part of a multiple drug regimen; maximum daily dose: 1500 mg/",
"     <b>",
"      day",
"     </b>",
"     (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Tuberculosis, drug-resistant:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants, Children, and Adolescents &le;14 years: I.M., I.V.: 15-30 mg/kg/dose once daily as part of a multiple drug regimen; maximum daily dose: 1000 mg/",
"     <b>",
"      day",
"     </b>",
"     (ATS/CDC/IDSA, 2003; CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents &ge;15 years, HIV-exposed/-positive: I.M., I.V.: 15 mg/kg/dose once daily as part of a multiple drug regimen for the first 2-3 months; maximum daily dose: 1000 mg/",
"     <b>",
"      day",
"     </b>",
"     (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Peritonitis (CAPD):",
"     </b>",
"     Intraperitoneal: Continuous: Loading dose: 25 mg per liter of dialysate; maintenance dose: 12 mg per liter (Warady, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Individualization is critical because of the low therapeutic index",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial and periodic peak and trough plasma drug levels should be determined, particularly in critically ill patients with serious infections or in disease states known to significantly alter aminoglycoside pharmacokinetics (eg, cystic fibrosis, burns, or major surgery). Manufacturer recommends a maximum daily dose of 15 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     (or 1500 mg/",
"     <b>",
"      day",
"     </b>",
"     in heavier patients). Higher doses may be warranted based on therapeutic drug monitoring or susceptibility information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     I.M., I.V.: 5-7.5 mg/kg/dose every 8 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Some clinicians suggest a daily dose of 15-20 mg/kg for all patients with normal renal function. This dose is at least as efficacious with similar, if not less, toxicity than conventional dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hospital-acquired pneumonia (HAP):",
"     </b>",
"     I.V.: 20 mg/kg/day with antipseudomonal beta-lactam or carbapenem (ATS guidelines, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Meningitis (susceptible gram-negative organisms):",
"     </b>",
"     I.V.: 5 mg/kg every 8 hours (administered with another bacteriocidal drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Mycobacterium fortuitum",
"      </i>",
"      ,",
"      <i>",
"       M. chelonae",
"      </i>",
"      , or",
"      <i>",
"       M. abscessus",
"      </i>",
"      :",
"     </b>",
"     I.V.: 10-15 mg/kg daily for at least 2 weeks with high-dose cefoxitin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants, Children, and Adolescents: I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     The following adjustments have been recommended (Aronoff, 2007);",
"     <b>",
"      Note:",
"     </b>",
"     Renally adjusted dose recommendations are based on doses of   5-7.5 mg/kg/dose every 8 hours:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 12-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 18-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 48-72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Intermittent hemodialysis: 5 mg/kg/dose; redose as indicated by serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Peritoneal dialysis (PD):  5 mg/kg/dose; redose as indicated by serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): 7.5 mg/kg/dose every 12 hours, monitor serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Some patients may require larger or more frequent doses if serum levels document the need (ie, cystic fibrosis or febrile granulocytopenic patients):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: Administer every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-60 mL/minute: Administer every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-40 mL/minute: Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Loading dose, then monitor levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (20%; variable; dependent on filter, duration, and type of HD): 5-7.5 mg/kg every 48-72 hours. Follow levels. Redose when pre-HD serum concentration &lt;10 mg/L; redose when post-HD serum concentration &lt;6-8 mcg/mL (Heintz, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peritoneal dialysis (PD): Dose as Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Follow levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     CVVH/CVVHD/CVVHDF: Loading dose of 10 mg/kg followed by maintenance dose of 7.5 mg/kg every 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     For severe gram-negative rod infections, target peak serum concentration of 15-30 mcg/mL; redose when serum concentration &lt;10 mcg/mL (Heintz, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate: 250 mg/mL (2 mL, 4 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Administer other antibiotics, such as penicillins and cephalosporins, at least 1 hour before or after an amikacin dose; simultaneous administration may result in reduced antibacterial efficacy. Administer around-the-clock to promote less variation in peak and trough serum levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: Administer undiluted I.M into large muscle mass. Slower absorption and lower peak concentrations, probably due to poor circulation in the atrophic muscle, may occur following I.M. injection; in paralyzed patients, suggest I.V. route",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. intermittent infusion: Infuse over 30-60 minutes; in infants infusion over 1-2 hours is recommended by the manufacturer. Final concentration should not exceed 10 mg/mL.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F132996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 75 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      10",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W, LR, mannitol 20%,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, aldesleukin, amifostine, amiodarone, amsacrine, anidulafungin, aztreonam, bivalirudin, caffeine citrate, caspofungin, cefepime, ceftazidime, cisatracurium, cyclophosphamide, cyclosporine, dexamethasone sodium phosphate, dexmedetomidine, diltiazem, docetaxel, doripenem, enalaprilat, esmolol, etoposide phosphate, fenoldopam, filgrastim, fluconazole, fludarabine, foscarnet, FreAmine&reg; III, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, idarubicin, IL-2, labetalol, levofloxacin, linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, midazolam, milrinone, morphine, nicardipine, ondansetron, oxytocin, paclitaxel, pemetrexed, piperacillin/tazobactam, remifentanil, sargramostim, teniposide, thiotepa, tigecycline, TrophAmine&reg;, vinorelbine, warfarin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amphotericin B cholesteryl sulfate complex, azithromycin, hetastarch in lactate electrolyte injection (Hextend&reg;), pantoprazole, propofol.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Furosemide, heparin, TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, clindamycin, doxapram, lidocaine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Heparin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13185685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); dilutions of 0.25 mg/mL and 5 mg/mL are stable for 24 hours under room temperature and 60 days at refrigeration in the following solutions: D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS,  D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, NS, LR",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of serious infections (bone and respiratory infections, endocarditis, and septicemia) due to organisms resistant to gentamicin and tobramycin, including",
"     <i>",
"      Pseudomonas",
"     </i>",
"     ,",
"     <i>",
"      Klebsiella",
"     </i>",
"     ,",
"     <i>",
"      Enterobacter",
"     </i>",
"     ,",
"     <i>",
"      Serratia",
"     </i>",
"     ,",
"     <i>",
"      Proteus",
"     </i>",
"     , and",
"     <i>",
"      Providencia",
"     </i>",
"     species, and",
"     <i>",
"      E. coli",
"     </i>",
"     (FDA approved in all ages); has also been used for documented infection of susceptible mycobacterial organisms",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F132998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amikacin may be confused with Amicar&reg;, anakinra",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amikin&reg; may be confused with Amicar&reg;, Kineret&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F132995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Neurotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ototoxicity (auditory), ototoxicity (vestibular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephrotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, dyspnea, eosinophilia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amikacin sulfate, any component, or other aminoglycosides",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use  with caution in patients with pre-existing renal impairment; modify dosage in patients with renal impairment; monitor renal and eighth nerve function in patients with known or suspected renal impairment",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Use with caution in patients with auditory or vestibular impairment. Use with caution in patients with myasthenia gravis, hypocalcemia, and in conditions which depress neuromuscular transmission; may cause neuromuscular blockade and respiratory paralysis; risk increased with concomitant use of anesthesia or muscle relaxants. Use with caution in pediatric patients on extracorporeal membrane oxygenation (ECMO); pharmacokinetics of aminoglycosides may be altered; dosage adjustment and close monitoring necessary.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Cross-allergenicity with other aminoglycosides has been observed. Avoid intramuscular administration in paralyzed patients, due to poor circulation in the atrophic muscles which may result in slower absorption and lower peak serum concentrations; use intravenous route.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aminoglycosides are associated with significant nephrotoxicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Vestibular and permanent bilateral auditory ototoxicity can occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; tinnitus or vertigo are indications of vestibular injury and impending bilateral irreversible deafness. Risk of nephrotoxicity and ototoxicity is increased in patients with impaired renal function, dehydration, high-dose therapy, or prolonged therapy. Peak and trough serum concentrations should be monitored periodically during therapy to assure adequate concentrations are achieved and to avoid potentially toxic levels",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Ototoxicity is associated with high serum concentrations persisting for prolonged periods; nephrotoxicity is associated with high serum trough concentrations. Risk of nephrotoxicity increases when used concurrently with other potentially nephrotoxic drugs",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; renal damage is usually reversible. Risk of ototoxicity increases with use of potent diuretics",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; may cause neuromuscular blockade and respiratory paralysis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk increased with concomitant use of anesthesia or muscle relaxants. Prolonged use may result in fungal or bacterial superinfection , including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Not intended for long-term therapy due to toxic hazards associated with extended administration. Aminoglycosides can cause fetal harm when administered to a pregnant woman and have been associated with several reports of total irreversible bilateral congenital deafness in pediatric patients exposed",
"     <i>",
"      in utero",
"     </i>",
"     . Some products contain sulfites which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Aminoglycosides may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F132918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5722003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; however, renal toxicity has been reported in additional studies. Amikacin crosses the placenta, produces detectable serum levels in the fetus, and concentrates in the fetal kidneys. Because of several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy, the manufacturer classifies amikacin as pregnancy risk factor D. Although serious side effects to the fetus have not been reported following maternal use of amikacin, a potential for harm exists.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of amikacin may be altered. Pregnant women have an average-to-larger volume of distribution which may result in lower peak serum levels than for the same dose in nonpregnant women. Serum half-life may also be shorter.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinalysis, urine output, BUN, serum creatinine, peak and trough serum amikacin concentrations; be alert to ototoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     With conventional  dosing, typically obtain serum concentration after the third dose; exceptions for earlier monitoring may include neonates or patients with rapidly changing renal function. With extended-interval dosing, usually obtain serum concentration after first, second, or third dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Not all infants and children who receive aminoglycosides require monitoring of serum aminoglycoside concentrations. Indications for use of aminoglycoside serum concentration monitoring include:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Treatment course &gt;5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients with decreased or changing renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients with poor therapeutic response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neonates and Infants &lt;3 months of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atypical body constituency (obesity, expanded extracellular fluid volume)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Clinical need for higher doses or shorter intervals (eg, cystic fibrosis, burns, endocarditis, meningitis, critically ill patients, relatively resistant organisms)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients on hemodialysis or chronic ambulatory peritoneal dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Signs of nephrotoxicity or ototoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Concomitant use of other nephrotoxic agents",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1045018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Therapeutic levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Life-threatening infections: 25-40 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serious infections: 20-25 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Urinary tract infections: 15-20 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Trough: &lt;8 mcg/mL; the American Thoracic Society (ATS) recommends trough levels of &lt;4-5 mcg/mL for patients with hospital-acquired pneumonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Timing of serum samples: Draw peak 30 minutes after completion of 30-minute infusion or at 1 hour following initiation of infusion or I.M. injection; draw trough within 30 minutes prior to next dose; aminoglycoside levels measured from blood taken from Silastic&reg; central catheters can sometimes give falsely elevated readings",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits protein synthesis in susceptible bacteria by binding to 30s and 50s ribosomal subunits resulting in a defective bacterial cell membrane",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13185701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Displays concentration-dependent killing; bacteriocidal",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Poorly absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.25 L/kg; primarily into extracellular fluid (highly hydrophilic); 12% of serum concentration penetrates into bronchial secretions; poor penetration into the blood-brain barrier even when meninges are inflamed; V",
"     <sub>",
"      d",
"     </sub>",
"     is increased in neonates and patients with edema, ascites, fluid overload; V",
"     <sub>",
"      d",
"     </sub>",
"     is decreased in patients with dehydration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein-binding: &le;11%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Low birth weight, 1-3 days of age: 7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Full-term &gt;7 days: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1.6-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: 1.5 &plusmn; 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Normal renal function: 1.4-2.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anuria: 28-86 hours; half-life and clearance are dependent on renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Within 45-120 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Within 30 minutes following a 30-minute infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (94% to 98%); excreted unchanged via glomerular filtration within 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Dialyzable (50% to 100%); supplemental dose recommended after hemodialysis or peritoneal dialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1045012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/57/6036?source=see_link\">",
"      see \"Amikacin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drink adequate amounts of water unless instructed to restrict fluid intake. May experience ringing in ears, dizziness, blurred vision, GI upset, loss of appetite, or photosensitivity. Report severe headache, changes in hearing acuity, ringing in ears, change in balance, changes in urine pattern, persistent diarrhea, respiratory difficulty, rash, fever, unhealed sores, sores in mouth, vaginal drainage, muscle or bone pain, change in gait, or worsening of condition.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F15572663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides",
"     <i>",
"      in vitro",
"     </i>",
"     . This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy",
"     <i>",
"      in vivo",
"     </i>",
"     , particularly in the setting of profound renal impairment; however, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allegaert K, Anderson BJ, Cossey V, et al, \"Limited Predictability of Amikacin Clearance in Extreme Premature Neonates at Birth,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2006, 61(1):39-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/16390350/pubmed\" id=\"16390350\" target=\"_blank\">",
"        16390350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Allegaert K, Scheers I, Cossey V, et al, \"Covariates of Amikacin Clearance in Neonates: The Impact of Postnatal Age on Predictability,\"",
"      <i>",
"       Drug Metab Lett",
"      </i>",
"      , 2008, 2(4):286-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/19356107/pubmed\" id=\"19356107\" target=\"_blank\">",
"        19356107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society and Infectious Diseases Society of America, \"Guidelines for the Management of Adults With Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia,\"",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2005, 171(4):388-416.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/15699079/pubmed\" id=\"15699079\" target=\"_blank\">",
"        15699079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society, CDC, and Infectious Diseases Society of America, \"Treatment of Tuberculosis,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2003, 52(RR-11):1-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/12836625/pubmed\" id=\"12836625\" target=\"_blank\">",
"        12836625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/pdf/rr/rr5811.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/pdf/rr/rr5811.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009a, 58(RR-4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Engle WA and American Academy of Pediatrics Committee on Fetus and Newborn, \"Age Terminology During the Perinatal Period,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(5):1362-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/15520122/pubmed\" id=\"15520122\" target=\"_blank\">",
"        15520122",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flume PA, Mogayzel PJ Jr, Robinson KA, et al, \"Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations,\"",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2009, 180(9):802-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/19729669/pubmed\" id=\"19729669\" target=\"_blank\">",
"        19729669",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilbert VE, Beals JD Jr, Natelson SE, et al, \"Treatment of Cerebrospinal Fluid Leaks and Gram-Negative Bacillary Meningitis With Large Doses of Intrathecal Amikacin and Systemic Antibiotics,\"",
"      <i>",
"       Neurosurgery",
"      </i>",
"      , 1986, 18(4):402-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/3754626/pubmed\" id=\"3754626\" target=\"_blank\">",
"        3754626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, and Dager WE, \"Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kasiakou SK, Rafailidis PI, Liaropoulos K, et al, \"Cure of Post-Traumatic Recurrent Multiresistant Gram-Negative Rod Meningitis With Intraventricular Colistin,\"",
"      <i>",
"       J Infect",
"      </i>",
"      , 2005, 50(4):348-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/15845435/pubmed\" id=\"15845435\" target=\"_blank\">",
"        15845435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kenyon CF, Knoppert DC, Lee SK, et al, &ldquo;Amikacin Pharmacokinetics and Suggested Dosage Modifications for the Preterm Infant,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1990, 34(2):265-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/2327775/pubmed\" id=\"2327775\" target=\"_blank\">",
"        2327775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Labaune JM, Bleyzac N, Maire P, et al, \"Once-a-Day Individualized Amikacin Dosing for Suspected Infection at Birth Based on Population Pharmacokinetic Models,\"",
"      <i>",
"       Biol Neonate",
"      </i>",
"      , 2001, 80(2):142-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/11509814/pubmed\" id=\"11509814\" target=\"_blank\">",
"        11509814",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Public Health Service Task Force on Prophylaxis and Therapy for",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"      Complex, &ldquo;Recommendations on Prophylaxis and Therapy for Disseminated",
"      <i>",
"       Mycobacterium avium",
"      </i>",
"      Complex Disease in Patients Infected With the Human Immunodeficiency Virus,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(12):898-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/8395019/pubmed\" id=\"8395019\" target=\"_blank\">",
"        8395019",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2012 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012, 808-16.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodr&iacute;guez Guardado A, Blanco A, Asensi V, et al, \"Multidrug-Resistant Acinetobacter Meningitis in Neurosurgical Patients With Intraventricular Catheters: Assessment of Different Treatments,\"",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2008, 61(4):908-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/18281693/pubmed\" id=\"18281693\" target=\"_blank\">",
"        18281693",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sherwin CM, Svahn S, Van der Linden A, et al, \"Individualised Dosing of Amikacin in Neonates: A Pharmacokinetic/Pharmacodynamic Analysis,\"",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 2009, 65(7):705-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/19305985/pubmed\" id=\"19305985\" target=\"_blank\">",
"        19305985",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(6):455-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/7667049 /pubmed\" id=\"7667049 \" target=\"_blank\">",
"        7667049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al, \"Practice Guidelines for the Management of Bacterial Meningitis,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(9):1267-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/15494903/pubmed\" id=\"15494903\" target=\"_blank\">",
"        15494903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vogelstein B, Kowarski A, and Lietman PS, &ldquo;The Pharmacokinetics of Amikacin in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1977, 91(2):333-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/43/12984/abstract-text/874697/pubmed\" id=\"874697\" target=\"_blank\">",
"        874697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12541 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_43_12984=[""].join("\n");
var outline_f12_43_12984=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708619\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132946\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045015\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11431469\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045008\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132922\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132905\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045020\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132996\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185685\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045019\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132998\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132995\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045023\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045007\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045006\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298732\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132915\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132918\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5722003\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045014\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045018\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045005\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185701\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045022\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045012\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15572663\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12541\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12541|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=related_link\">",
"      Amikacin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/57/6036?source=related_link\">",
"      Amikacin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_43_12985="Clavicle fractures";
var content_f12_43_12985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clavicle fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/43/12985/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/43/12985/contributors\">",
"     Robert L Hatch, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/43/12985/contributors\">",
"     James R Clugston, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/43/12985/contributors\">",
"     Jonathan Taffe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/43/12985/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/43/12985/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/43/12985/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/43/12985/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/43/12985/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clavicle fractures occur commonly, often as a result of indirect or direct trauma to the shoulder region. Clinicians working in emergency departments and general clinics should be familiar with the common presentations and complications of this injury, as well as basic management.",
"   </p>",
"   <p>",
"    This topic review will discuss the presentation and management of clavicle fractures. Other shoulder injuries and the approach to undifferentiated shoulder pain are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10663?source=see_link\">",
"     \"Acromioclavicular joint injuries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clavicle fractures account for approximately 2.6 percent of all fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The peak incidence occurs in children and young adults. Over one-third of clavicle fractures in males occur between the ages of 13 and 20 years, while 20 percent of clavicle fractures in women occur in the same age group [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/3\">",
"     3",
"    </a>",
"    ]. Incidence falls over subsequent decades before rising again in older men and women.",
"   </p>",
"   <p>",
"    In a study of 1000 consecutive fractures, 69 percent occurred in the middle third of the bone, 28 percent in the distal third, and 2.8 percent in the proximal third [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/3\">",
"     3",
"    </a>",
"    ]. Distal third fractures are further subdivided into three types [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/4\">",
"     4",
"    </a>",
"    ]. These locations provide the basis for clavicle fracture classification. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Classification'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In older studies, fractures of the proximal clavicle constituted only 2 to 3 percent of all clavicle fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. However, a subsequent study found that 9.3 percent of clavicle fractures involved the medial third [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/5\">",
"     5",
"    </a>",
"    ]. The authors hypothesized that their higher rate was due to the institution's liberal use of CT (22 percent of medial clavicle fractures were seen only on CT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clavicle is the first bone in the human skeleton to ossify [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/6\">",
"     6",
"    </a>",
"    ]. It serves as the only bony connection between the arm and the trunk, articulating distally with the acromion (acromioclavicular joint) and proximally with the sternum (sternoclavicular joint) (",
"    <a class=\"graphic graphic_figure graphicRef62016 \" href=\"UTD.htm?23/41/24210\">",
"     figure 1",
"    </a>",
"    ). These joints are referred to as atypical synovial joints, because they are lined by fibrocartilage rather than hyaline cartilage. The clavicle is secured to the scapula by the acromioclavicular and coracoclavicular ligaments and is bound to the sternum by the sternoclavicular ligaments.",
"   </p>",
"   <p>",
"    The clavicle is shaped like an &ldquo;S&rdquo;. The proximal half curves outward (convex) providing space for the neurovascular bundle of the upper limb. The distal half curves back (concave) before attaching to the scapula. Clavicle fractures usually occur at the junction (midshaft) between these two curves, most likely because this area lacks ligamentous attachments to adjacent bones and is the bone's thinnest segment.",
"   </p>",
"   <p>",
"    When displacement occurs, the proximal fragment of a clavicle fracture is almost always displaced superiorly (cephalad) by the pull of the sternocleidomastoid muscle, which attaches to the proximal portion of the clavicle (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52992 \" href=\"UTD.htm?43/14/44271\">",
"     image 1",
"    </a>",
"    ). The distal fragment is displaced inferiorly (caudad) by the weight of the arm (",
"    <a class=\"graphic graphic_figure graphicRef82691 \" href=\"UTD.htm?37/51/38705\">",
"     figure 2",
"    </a>",
"    ). Shortening often occurs (ie, the fractured bone ends are pulled past each other) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72980 \" href=\"UTD.htm?12/13/12511\">",
"     image 2",
"    </a>",
"    ). This is largely due to the subscapularis and pectoralis muscles, which rotate and pull the arm towards the chest.",
"   </p>",
"   <p>",
"    Even though the clavicle is subcutaneous, with only a thin layer of overlying soft tissue, open fractures are uncommon. However, tenting (ie, taught stretching) of the overlying skin is relatively common. If left uncorrected, tenting may lead to necrosis of the overlying skin and conversion to an open fracture. Tenting is therefore an indication for closed reduction or surgical repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allman classified clavicular fractures into three groups based upon location [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/7\">",
"     7",
"    </a>",
"    ]. Group I consists of fractures of the middle third, group II of the distal third, and group III of the proximal third. In a study of 1000 consecutive fractures, 69 percent occurred in the middle third of the bone, 28 percent in the distal third, and 2.8 percent in the proximal third [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/3\">",
"     3",
"    </a>",
"    ]. Distal third fractures are further subdivided into three types [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 87 percent of clavicle fractures are caused by a fall onto the shoulder [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/8\">",
"     8",
"    </a>",
"    ]. Traffic accidents and sports account for most fractures among the young [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/3\">",
"     3",
"    </a>",
"    ]. Of injuries caused by traffic accidents, 39 percent occur in cyclists, 26 percent in car drivers or passengers, 17 percent in pedestrians, and 17 percent in motorcyclists [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unusual causes of clavicle fractures include a direct blow from an object to the clavicle (7 percent) and indirect trauma from falls onto an outstretched hand (6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/8\">",
"     8",
"    </a>",
"    ]. There is no correlation between the mechanism of injury and the site of fracture (ie, which third is involved) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     FRACTURES OF THE MIDDLE THIRD (MIDSHAFT) OF THE CLAVICLE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical presentation and examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain in patients with fractures of the middle third of the clavicle is usually well localized and exacerbated by movement of the arm. The patient may describe a snapping or cracking sensation at the time of the injury and may notice localized swelling over the affected area.",
"   </p>",
"   <p>",
"    Because the clavicle lies close to the skin, examination often reveals a visible bulge due to hematoma (often with associated ecchymosis), bone angulation, or displaced bone edges. Tenting of the skin, if present, suggests significant angulation or displacement.",
"   </p>",
"   <p>",
"    There is point tenderness over the fracture site. In addition, firm pressure on the clavicle, even if not applied directly to the fracture site, may elicit crepitus or palpable motion of the fragment.",
"   </p>",
"   <p>",
"    It is important to perform a neurovascular and lung examination looking for other injuries in all patients with clavicle fractures, particularly if higher forces were involved (eg, motor vehicle collision). Additional complications that can occur with high force injuries include scapula fractures, rib fractures, hemothorax, pneumothorax, and brachial plexus injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Middle third fractures are usually transverse or oblique. Displacement and comminution (ie, the bone is broken into more than two pieces) are common (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54493 \" href=\"UTD.htm?7/9/7327\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In general, only a single anteroposterior (AP) view is required to demonstrate a middle third fracture and assess its position. Displacement almost always occurs in the vertical plane, which is shown in an AP view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52992 \" href=\"UTD.htm?43/14/44271\">",
"     image 1",
"    </a>",
"    ). If a fracture is suspected but the AP view is unrevealing, a 45 degree cephalic tilt view can be obtained to better assess the clavicle (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65790 \" href=\"UTD.htm?20/27/20913\">",
"     image 4",
"    </a>",
"    ). The clinician should also look closely for associated fractures of the scapula, particularly with high force injuries.",
"   </p>",
"   <p>",
"    Glenoid neck fracture, a type of scapula fracture, deserves special mention. A glenoid neck fracture combined with an ipsilateral clavicle fracture produces a \"floating shoulder\" in which there is no stable bony continuity between the upper extremity and the trunk. This unstable injury requires urgent orthopedic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A preliminary observational study suggests that ultrasound can accurately diagnose clavicle fractures at the bedside [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Indications for orthopedic referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of indications for orthopedic referral of midshaft clavicle fractures that vary in urgency.",
"   </p>",
"   <p>",
"    Emergent referral is required for open fractures, neurovascular compromise, and tenting of the skin (skin stretched tautly over a displaced fracture). An open fracture should be suspected anytime there is a break in the skin near a fracture site. After puncturing the skin during the initial injury, fractured bone ends often retract under the skin and cannot be seen with simple inspection.",
"   </p>",
"   <p>",
"    If respiratory compromise or hemodynamic instability exists, serious injury to intrathoracic or other structures should be suspected and immediately addressed. Such patients should be evaluated in the emergency department. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urgent referral is recommended for patients with a \"floating shoulder\" (ie, ipsilateral clavicle and glenoid neck fractures). Although various treatments are used for floating shoulder, operative repair appears to be superior in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The radiographic findings in midshaft fractures are discussed in the preceding section.",
"   </p>",
"   <p>",
"    Another indication for orthopedic referral is a completely displaced clavicle fracture, which is defined as displacement greater than one bone width. In the past, nonoperative treatment was recommended even if displacement was considerable. However, completely displaced fractures treated nonoperatively produce unsatisfactory results in over 30 percent of patients, with nonunion rates higher than previously thought (7 to 15 percent) and worse cosmetic results (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52992 \" href=\"UTD.htm?43/14/44271\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72980 \" href=\"UTD.htm?12/13/12511\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The improved outcomes for displaced midshaft fractures treated surgically was best demonstrated in a meta-analysis of six randomized trials involving 412 patients who were assigned to operative fixation or immobilization using a sling [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/17\">",
"     17",
"    </a>",
"    ]. According to this review, operative treatment resulted in significantly lower nonunion rates (3 vs 29 events (1% vs 15%); Risk Ratio 0.18, 95% CI 0.06-0.51) and lower complication rates, although the latter result did not reach statistical significance (62 vs 84 events (30% vs 42%); Risk Ratio 0.70, 95% CI 0.42-1.18). In addition, patients treated surgically had less pain during recovery and regained function faster than those managed conservatively. However, functional outcome scores obtained at one year follow-up favored surgical repair only modestly.",
"   </p>",
"   <p>",
"    Orthopedic referral is particularly important for displaced fractures with comminution (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54493 \" href=\"UTD.htm?7/9/7327\">",
"     image 3",
"    </a>",
"    ) or shortening (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72980 \" href=\"UTD.htm?12/13/12511\">",
"     image 2",
"    </a>",
"    ). Comminution confers a higher risk of nonunion and other long-term sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/18\">",
"     18",
"    </a>",
"    ]. Shortening greater than 18 mm in males and 14 mm in females confers a significant risk of morbidity, including local tenderness, numbness, pain when lying on the affected side, impaired range of motion, impaired strength, and cosmetic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Orthopedic referral may be helpful for less severely displaced fractures if the patient is active or athletic or is concerned about the appearance of a visible lump at the fracture site. It is best to discuss referral with the patient in such cases. Patients with a symptomatic malunion or a nonunion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60222 \" href=\"UTD.htm?31/32/32271\">",
"     image 5",
"    </a>",
"    ) after 12 to 16 weeks should be referred. No additional treatment is needed if a patient with malunion or nonunion is asymptomatic.",
"   </p>",
"   <p>",
"    Although the angulation of some clavicle fractures can be impressive, the degree of angulation alone is not a decisive factor for orthopedic referral.&nbsp;Instead, the clinician should assess for the referral indications described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Initial nonoperative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative treatment produces good results with nondisplaced middle third clavicle fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. Provided there are no indications for referral, we recommend the approach described below for patients with nondisplaced fractures and for those with displaced fractures who are poor operative candidates or prefer to avoid surgery. Even if displacement is present, most patients have good outcomes with conservative treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goal of treatment for middle third fractures is pain control and reduction of motion at the fracture site until clinical union occurs. Icing intermittently during the first 48 to 72 hours helps control both pain and swelling. We recommend applying ice packs for 20 to 30 minutes every one to three hours while awake.",
"   </p>",
"   <p>",
"    Adequate pain control is generally achieved with moderate strength opioids initially (eg, hydrocodone or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    alone after three to seven days. The use of nonsteroidal antiinflammatory drugs in fractures is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of selective COX-2 inhibitors\", section on 'Possible effect on fracture healing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The fracture site is best stabilized by restricting shoulder motion to less than 30 degrees of abduction, forward flexion, or extension. Either a sling or a figure of eight bandage (",
"    <a class=\"graphic graphic_picture graphicRef68236 \" href=\"UTD.htm?18/13/18640\">",
"     picture 1",
"    </a>",
"    ) can be used. Outcomes are similar but each approach has advantages and disadvantages [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A sling is more comfortable and, in a small randomized trial, produced greater patient satisfaction than a figure of eight bandage [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/21\">",
"       21",
"      </a>",
"      ]. However, the sling limits use of the affected arm and may cause the elbow to stiffen if the patient does not conscientiously perform range of motion exercises.",
"     </li>",
"     <li>",
"      In contrast to the sling, the figure of eight bandage leaves the elbow and hand free for daily activities, avoids elbow stiffness, and has the potential to correct fracture shortening. However, the figure of eight bandage has a number of potential limitations:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It must be adjusted frequently to keep it tight and maintain the shoulders in a \"position of attention\". Patients often find this uncomfortable.",
"     </li>",
"     <li>",
"      Tightening of the figure of eight bandage is performed from behind and requires assistance. Hence, it is not a good choice for the patient who lives alone.",
"     </li>",
"     <li>",
"      Excessive tightening of the bandage increases the risk for skin breakdown, upper extremity edema, and brachial plexus palsy.",
"     </li>",
"     <li>",
"      It may not provide enough support during early treatment, which is easily addressed by temporarily adding a sling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For middle third fractures that are nondisplaced or have less than complete displacement, we suggest treatment with a sling and daily elbow range of motion exercises several times per day to maintain full flexion and extension. Range of motion exercises, which should be started no later than three to five days after injury, are performed with the arm being removed from the sling and the elbow maximally extended and maximally flexed several times. The forearm should be pronated and supinated several times as well.",
"   </p>",
"   <p>",
"    For patients with complete displacement who decline surgery, we suggest treatment with a figure of eight bandage, which may help to correct or prevent shortening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Follow-up care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immobilization with either a sling or figure of eight bandage is continued until clinical union occurs (ie, the fracture site is nontender and the patient can move the arm fully with little or no discomfort). Follow-up visits begin one to two weeks after injury to assess clinical symptoms, and every two to three weeks thereafter until the patient is asymptomatic and shoulder function is satisfactory. While the shoulder is immobilized, the arm can be used as symptoms allow, but strenuous activities should be avoided. Patients treated with a sling are encouraged to perform elbow range of motion exercises to maintain normal function and prevent stiffness.",
"   </p>",
"   <p>",
"    Clinical union usually occurs by 6 to 12 weeks in adults and 3 to 6 weeks in children. Radiographs are usually obtained at this point, although callus may not appear for several more weeks. If clinical union has occurred, immobilization can be discontinued even if callus is not seen. Radiographs can be repeated four to six weeks later if there is a need to document radiographic union (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75521 \" href=\"UTD.htm?1/0/1039\">",
"     image 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    After immobilization is discontinued, patients should be advised to perform shoulder range of motion and strengthening exercises to hasten recovery. Supervision by physical therapists facilitates this process, particularly early on.",
"   </p>",
"   <p>",
"    Patients should be informed that callus formation during healing may produce a prominent lump at the fracture site. In children, the callus usually remodels and disappears. This occurs to a lesser extent in adults, and most will have a persistent, visible lump.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious complications are uncommon after middle third clavicle fractures. Neurovascular complications at presentation or after reduction are rare and include subclavian artery or vein compression, thoracic outlet syndrome, and brachial plexus injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link\">",
"     \"Brachial plexus syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malunion is the most common complication and may result in angulation, shortening, or a poor cosmetic result. Even with malunion, patients often have acceptable function. Some malunions may cause functional or neurologic problems, particularly if there is shortening greater than 2 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/22\">",
"     22",
"    </a>",
"    ]. Delayed operative correction of the shortening improves symptoms in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonunion occurs when the fracture fails to heal after four to six months. Predisposing factors include greater initial displacement, severe trauma, comminution, shortening, primary open reduction, older age, and inadequate immobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/15,23\">",
"     15,23",
"    </a>",
"    ]. A late complication occasionally associated with nonunion is brachial plexus compression neuropathy resulting from hypertrophic callus formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pediatric considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among children, 90 percent of clavicle fractures occur in the middle third [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/1\">",
"     1",
"    </a>",
"    ]. In children 10 and under, 60 percent of clavicle fractures are nondisplaced. Above age 10, the majority are displaced (as in adults) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment does not differ from adults. Healing occurs more quickly, and immobilization is generally necessary for only three to four weeks. Contact sports and hard blows to the shoulder should be avoided for an additional two to three weeks. Bowing of the clavicle (bending of the bone without overt disruption of the cortex) may occur in young children. This injury should be treated like other clavicle fractures to prevent progression to an overt fracture.",
"   </p>",
"   <p>",
"    Clavicle fractures reportedly comprise 95 percent of fractures during childbirth [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/24\">",
"     24",
"    </a>",
"    ]. In the newborn, such fractures are more commonly associated with difficult deliveries, such as shoulder dystocia or breech. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41752?source=see_link\">",
"     \"Intrapartum management and outcome of shoulder dystocia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     FRACTURES OF THE DISTAL THIRD OF THE CLAVICLE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinical presentation and examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the distal clavicle are easily confused with acromioclavicular (AC) separations. Both present with pain and tenderness around the AC joint, often with swelling and ecchymosis. The cross arm test (adduction of the arm across the chest) increases pain in both conditions. Little or no deformity is seen on examination, unless a type II fracture is present (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57129 \" href=\"UTD.htm?0/47/767\">",
"     image 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The types of distal clavicular fractures are described in the next section. The location of maximal tenderness may provide a clue to the diagnosis. With fractures, maximal tenderness is usually located medial to the AC joint, instead of directly over the joint. Nevertheless, radiography is necessary to differentiate between the two injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal third clavicle fractures are divided into three types based upon fracture site and ligamentous stability (",
"    <a class=\"graphic graphic_figure graphicRef68939 \" href=\"UTD.htm?22/10/22688\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82269 \" href=\"UTD.htm?7/0/7168\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58705 \" href=\"UTD.htm?13/28/13760\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66402 \" href=\"UTD.htm?15/41/16016\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Type I fractures are most common. In this injury, intact ligaments hold the proximal and distal fragments in alignment and no displacement occurs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76058 \" href=\"UTD.htm?5/51/5936\">",
"     image 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In type II fractures, the proximal (medial) fragment loses its ligamentous attachment and is displaced superiorly (cephalad) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57129 \" href=\"UTD.htm?0/47/767\">",
"     image 7",
"    </a>",
"    ). This may occur in two ways: type IIA in which the coracoclavicular ligament is not torn but inserts only on the distal fragment, and type IIB in which the coracoclavicular ligament is torn.",
"   </p>",
"   <p>",
"    Type II fractures are difficult to diagnose on standard radiographs. Oblique views (45 degrees anterior and posterior) or stress views of both shoulders (10 pound weight strapped to each wrist to exaggerate displacement) are often needed to demonstrate displacement.",
"   </p>",
"   <p>",
"    Type III fractures are intraarticular, extending into the AC joint (",
"    <a class=\"graphic graphic_figure graphicRef66402 \" href=\"UTD.htm?15/41/16016\">",
"     figure 6",
"    </a>",
"    ). Type III injuries are easily overlooked, as the fracture line may be subtle and intact ligaments generally prevent displacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Indications for orthopedic referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend orthopedic referral for all type II distal clavicle fractures because they are prone to complications and treatment remains controversial. Operative repair is recommended by some authors, and a wide range of surgical approaches has been used [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. Others report that although nonunion and delayed union are common (approximately 30 percent), conservative therapy generally provides a good functional outcome and avoids the high complication rates associated with surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One small retrospective study compared 16 patients with type II fractures treated conservatively with 14 treated operatively and found no difference in functional outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Referral is reasonable for patients with type III distal clavicle fractures. These fractures extend into the AC joint and are theoretically prone to future degenerative change, which may limit shoulder function. Patients who choose nonoperative management should be made aware of these potential risks.",
"   </p>",
"   <p>",
"    Little data is available on outcomes for type III fractures and findings are contradictory. One observational study found a high rate of later AC joint arthrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/4\">",
"     4",
"    </a>",
"    ]. In a subsequent observational study with 15 years of follow-up, only 1 of 14 patients had pain, and ROM was no different than patients with other distal clavicle fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/33\">",
"     33",
"    </a>",
"    ]. In the event of future problems, both patient and clinician may be more content knowing that specialty care was provided, or at least offered. If the patient declines referral, conservative care can be provided as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I and type III distal clavicle fractures are usually minimally displaced and heal well with conservative therapy. Immobilization in a sling provides comfort.",
"   </p>",
"   <p>",
"    Conservative treatment of type II fractures involves supporting the weight of the arm to keep the edge of the proximal fragment as close as possible to the coracoid process. The goal is to foster healing in an anatomic position and this can be achieved with a sling [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/31\">",
"     31",
"    </a>",
"    ]. A figure of eight bandage should NOT be used for type II fractures, as it does not support the weight of the arm and may increase displacement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early movement of the glenohumeral joint is encouraged, beginning as soon as symptoms permit, to prevent development of a frozen shoulder [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/31\">",
"     31",
"    </a>",
"    ]. Range of motion exercises can begin with the arm in a sling. Pendulum exercises are useful initially. To perform them, the patient bends forward at the waist, dangles the arm in the sling and gently makes circles with the arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Follow-up care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up appointments are needed every two to three weeks until symptoms resolve and satisfactory shoulder function is achieved. Immobilization with a sling is continued until clinical healing has occurred (resolution of pain and tenderness). This usually requires three to six weeks. Once the patient regains full and painless shoulder range of motion, strengthening exercises are begun [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonunion is uncommon with nondisplaced distal clavicle fractures (ie, types I and III) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/28\">",
"     28",
"    </a>",
"    ]. However, nonunion is common with type II fractures (22 to 33 percent), as is delayed union (45 to 67 percent require over three months to heal) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible late complication of intraarticular (type III) fractures is degenerative change within the AC joint. In such cases, plain films usually demonstrate osteophytes, narrowing of the joint space, or resorption of the distal clavicle. Initially, symptoms should be managed with conservative therapy, such as a short course of oral nonsteroidal medication or a local steroid injection. If several attempts at conservative management fail to control symptoms or function is compromised, resection of the distal clavicle may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pediatric considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with type II fractures, the periosteal sleeve generally remains intact. This prevents displacement and makes type II fractures in children more stable than in adults. Any nondisplaced distal clavicle fracture in a child (type I, II, or III) can be managed with sling immobilization for comfort and early range-of-motion exercises as soon as pain permits. Healing usually occurs in four to six weeks. Displaced fractures should be referred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     FRACTURES OF THE PROXIMAL THIRD OF THE CLAVICLE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Clinical presentation and examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both acute fractures and stress fractures may occur in the proximal (or medial) third of the clavicle. Although least common among the different clavicle fracture types, acute proximal fractures are most often associated with serious injury: 84 percent are caused by vehicular trauma, 90 percent involve multisystem trauma, and 20 percent of patients die within one month of their injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/5\">",
"     5",
"    </a>",
"    ]. Deaths are not due to injuries directly caused by the clavicle fracture, but rather by associated chest, head, neck and visceral trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients with major trauma should be thoroughly evaluated in the emergency department. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stress fractures develop insidiously from repetitive stress on the proximal clavicle related to a range of activities, including: rowing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/34\">",
"     34",
"    </a>",
"    ], gymnastics [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/35\">",
"     35",
"    </a>",
"    ], cable-making [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/36\">",
"     36",
"    </a>",
"    ], and even nervous tics [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/37\">",
"     37",
"    </a>",
"    ]. In patients with persistent pain in the sternoclavicular area and no history of acute trauma, particularly those who engage in repetitive activities involving clavicle motion, a stress fracture may be the cause. Evaluation generally begins with plain x-rays, followed by CT if necessary. Additional studies are occasionally needed to exclude other causes of bone pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"     \"Overview of stress fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both acute and stress fractures of the proximal clavicle usually present with pain near the sternoclavicular area, worsened by movement of the shoulder. The supine position may increase pain, and patients are usually more comfortable if they sit up and support the arm, although trauma patients are not permitted to do so until cervical injury is ruled out [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In acute fractures, ecchymosis may be noted, especially if significant ligamentous injury and displacement of fracture fragments has occurred. An anteriorly (or outwardly) protruding medial clavicle suggests an anterior sternoclavicular dislocation, but may be caused by a medial fracture (sometimes called a \"pseudo-dislocation\" of the sternoclavicular joint) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/38\">",
"     38",
"    </a>",
"    ]. When the medial clavicle is displaced posteriorly (or inwardly), it is often difficult to palpate. This finding suggests a posterior sternoclavicular dislocation. However, in young patients, it may represent a physeal fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to perform a neurovascular and lung examination looking for other injuries in all patients with clavicle fractures, particularly if higher forces were involved (eg, motor vehicle collision). Additional complications that can occur with high force injuries include scapula fractures, rib fractures, hemothorax, pneumothorax, and brachial plexus injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal clavicle fractures may occasionally be missed on standard AP radiographs due to overlying bony shadows. X-rays of each shoulder using a 45 degree cephalic tilt view and careful comparisons of the injured and uninjured sides may reveal the injury (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65790 \" href=\"UTD.htm?20/27/20913\">",
"     image 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/2\">",
"     2",
"    </a>",
"    ]. Proximal fractures are also difficult to see on radiographs if the costoclavicular ligaments remain attached to the outer fragment, as displacement is minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical and radiographic evidence of swelling in the medial clavicle may falsely suggest a neoplastic or inflammatory process. Further imaging is often necessary to rule out such pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computed tomography (CT) and magnetic resonance imaging enable clinicians to distinguish fractures from other injuries and to assess the patient for other serious injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/5,39,40\">",
"     5,39,40",
"    </a>",
"    ]. One case series found that no acute medial clavicle fractures were missed by CT scan, while 22 percent were missed on plain radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Indications for referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with acute medial third clavicle fractures should be carefully evaluated in the emergency department for associated head, neck, chest, and visceral injuries. The incidence of serious associated injuries is approximately 90 percent. Emergent surgical repair is necessary for open clavicle fractures and for any significant intrathoracic or neurovascular injury from posterior displacement of fracture fragments [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with significant displacement of a fracture fragment (greater than one centimeter), posterior displacement, or posterior sternoclavicular dislocation should be urgently referred to an orthopedist after other injuries have been excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management of nondisplaced proximal clavicle fractures, such as stress fractures, is nonoperative and involves ice, analgesics, and a sling for support [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/41\">",
"     41",
"    </a>",
"    ]. Use of the arm is allowed as symptoms permit [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/2\">",
"     2",
"    </a>",
"    ]. All other injuries are managed by the orthopedic surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Follow-up care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most uncomplicated, acute proximal clavicle fractures are successfully managed with immobilization in a sling. Healing generally occurs within six to eight weeks. Definitive management is similar to that for type I and III distal clavicle fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians describe the successful treatment of medial clavicle stress fractures with cessation of the inciting activity for several weeks followed by physical therapy to improve posture, scapulothoracic mechanics, and rotator cuff strength [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. This is followed by a gradual, progressive return to sport. Return to full training and competition may require two months or longer following diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonunion and posttraumatic arthritis are the most frequent complications of proximal clavicle fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/2\">",
"     2",
"    </a>",
"    ]. Inward sternoclavicular dislocations or inwardly displaced fracture fragments may cause severe injuries, including pneumothorax, subclavian vessel laceration, and brachial plexus compression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest published series of medial third fractures, 32 patients were followed for an average of 15 months. Forty-seven percent of patients had no pain, but 25 percent had mild ongoing pain, 22 percent had moderate pain, and 6 percent had severe pain at follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/5\">",
"     5",
"    </a>",
"    ]. This is somewhat higher than with most fractures, perhaps related to the severe trauma that usually causes these fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Pediatric considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with adults, children rarely sustain proximal clavicle fractures. When present, these fractures usually involve the physis near the sternoclavicular (SC) joint; true SC dislocations generally do not occur in children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/6,40\">",
"     6,40",
"    </a>",
"    ]. The physis adjacent to the SC joint is the last in the body to close; fusion to the clavicle shaft occurs at 23 to 25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in adults, initial evaluation is performed with plain radiographs. A CT scan can help delineate injuries to the region of the proximal clavicle in patients with severe injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/6\">",
"     6",
"    </a>",
"    ]. Medial clavicle physeal injuries sometimes produce only minimal symptoms without deformity and may not be identified until a healing callus becomes visible radiographically at the fracture site [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pediatric patients with nondisplaced medial clavicle fractures may be placed in a sling for comfort and instructed to begin range of motion exercises as pain allows. Anteriorly displaced fractures can generally be treated without reduction because the displacement is usually well tolerated and in most cases the bone remodels [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/2\">",
"     2",
"    </a>",
"    ]. Fractures with posterior displacement should be referred and may be treated with open reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/39\">",
"     39",
"    </a>",
"    ]. This is done emergently if any sign of neurovascular compromise exists.",
"   </p>",
"   <p>",
"    As in adults with medial clavicle fractures, it is important to maintain a high index of suspicion for other injuries. The patient should be evaluated in an emergency department if significant trauma was involved or if symptoms or clinical findings suggest a serious concurrent injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     RETURN TO WORK OR SPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The return to work or sport is individualized based upon patient age, fracture location and severity, the degree of clinical and radiological healing, and the work or sport activity in question [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/23\">",
"     23",
"    </a>",
"    ]. Most patients return to preinjury levels of activity within six to eight weeks.",
"   </p>",
"   <p>",
"    In general, patients with distal third fractures return to preinjury levels of activity sooner than those with middle third fractures, sometimes as soon as four to six weeks. Patients should avoid contact sports and strenuous activities until four weeks after clinical healing to allow sufficient healing at the fracture site.",
"   </p>",
"   <p>",
"    Generally speaking, athletes should not return to sport until they have full range of motion, normal strength of the shoulder, and no pain with forceful palpation over the fracture site [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/23\">",
"     23",
"    </a>",
"    ]. Those involved in noncontact sports can generally return to play by six weeks while those involved in contact sports require 8 to 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For contact sport athletes who have had operative management, some experts recommend removing hardware before return to play [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/43\">",
"     43",
"    </a>",
"    ]. Hardware is typically removed one year after placement. To reduce the risk of refracture, patients should allow approximately six to eight weeks after removal for the screw holes to fill with bone before returning to play [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12985/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=see_link\">",
"       \"Patient information: Fractures (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39330?source=see_link\">",
"       \"Patient information: Clavicle fracture (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clavicle fractures are categorized by location, with approximately 69 percent occurring in the middle third, 28 percent in the distal third, and 3 percent in the proximal third. Acute fractures of the proximal third of the clavicle often stem from high energy trauma and are associated with severe internal injury. Most clavicle fractures are caused by a fall onto the shoulder; traffic accidents and sports account for most fractures among the young. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to assess vital signs and to perform a neurovascular and lung examination in all patients with clavicle fractures, particularly if the cause involved higher energy forces (eg, motor vehicle collision). Patients involved in high energy trauma or with symptoms or clinical findings suggestive of internal injury should be assessed in the emergency department.",
"     </li>",
"     <li>",
"      Emergent orthopedic referral is required for open fractures and fractures causing neurovascular compromise or tenting of the skin. Urgent referral is recommended for patients with a \"floating shoulder\" (ie, ipsilateral clavicle and glenoid neck fractures).",
"     </li>",
"     <li>",
"      Middle third clavicle fractures are often associated with displacement and comminution. In general, a single anteroposterior radiograph is sufficient for assessment. Orthopedic referral is needed for patients with a completely displaced clavicle fracture, which is defined as displacement greater than one bone width. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Fractures of the middle third (midshaft) of the clavicle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with nondisplaced or minimally displaced middle third fractures are treated with a sling, analgesics, and regular elbow range of motion exercises. For patients with complete displacement who decline surgery, immobilization using a figure of eight bandage may help to correct or prevent shortening, but a sling is acceptable.",
"     </li>",
"     <li>",
"      Clinically, fractures of the distal clavicle are easily confused with acromioclavicular separations. Radiographs are necessary to differentiate between the two. Orthopedic referral is recommended for most distal clavicle fractures. An exception is type I fractures confirmed by normal stress views using plain x-rays. Confirmed type I fractures can be managed using a sling and early shoulder range of motion exercises, begun as soon as symptoms allow. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Fractures of the distal third of the clavicle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute fractures of the proximal clavicle should alert the physician to the possibility of serious internal injury. In most cases, evaluation is performed in the emergency department. If there are no associated injuries and the fracture is nondisplaced, treatment involves sling immobilization. Stress fractures develop insidiously from repetitive stress on the proximal clavicle related to a range of activities, including rowing and gymnastics. Conservative treatment is generally successful. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Fractures of the proximal third of the clavicle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among children, 90 percent of clavicle fractures occur in the middle third. In children 10 and under, the majority are nondisplaced; above age 10, the majority are displaced. Treatment generally does not differ from that recommended for adults, but healing occurs more quickly. Special pediatric considerations for each type of clavicle fracture are described in the text.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/1\">",
"      Postacchini F, Gumina S, De Santis P, Albo F. Epidemiology of clavicle fractures. J Shoulder Elbow Surg 2002; 11:452.",
"     </a>",
"    </li>",
"    <li>",
"     Eiff, MP, Hatch, RL, Calmbach, W. Clavicle and scapula fractures. In: Fracture Management for Primary Care, 2nd ed, WB Saunders, Philadelphia 2002. p.198.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/3\">",
"      Robinson CM. Fractures of the clavicle in the adult. Epidemiology and classification. J Bone Joint Surg Br 1998; 80:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/4\">",
"      Neer CS 2nd. Fractures of the distal third of the clavicle. Clin Orthop Relat Res 1968; 58:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/5\">",
"      Throckmorton T, Kuhn JE. Fractures of the medial end of the clavicle. J Shoulder Elbow Surg 2007; 16:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/6\">",
"      Bishop JY, Flatow EL. Pediatric shoulder trauma. Clin Orthop Relat Res 2005; :41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/7\">",
"      Allman FL Jr. Fractures and ligamentous injuries of the clavicle and its articulation. J Bone Joint Surg Am 1967; 49:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/8\">",
"      Stanley D, Trowbridge EA, Norris SH. The mechanism of clavicular fracture. A clinical and biomechanical analysis. J Bone Joint Surg Br 1988; 70:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/9\">",
"      Herscovici D Jr, Fiennes AG, Allg&ouml;wer M, R&uuml;edi TP. The floating shoulder: ipsilateral clavicle and scapular neck fractures. J Bone Joint Surg Br 1992; 74:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/10\">",
"      Cross KP, Warkentine FH, Kim IK, et al. Bedside ultrasound diagnosis of clavicle fractures in the pediatric emergency department. Acad Emerg Med 2010; 17:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/11\">",
"      Edwards SG, Whittle AP, Wood GW 2nd. Nonoperative treatment of ipsilateral fractures of the scapula and clavicle. J Bone Joint Surg Am 2000; 82:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/12\">",
"      Leung KS, Lam TP. Open reduction and internal fixation of ipsilateral fractures of the scapular neck and clavicle. J Bone Joint Surg Am 1993; 75:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/13\">",
"      Canadian Orthopaedic Trauma Society. Nonoperative treatment compared with plate fixation of displaced midshaft clavicular fractures. A multicenter, randomized clinical trial. J Bone Joint Surg Am 2007; 89:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/14\">",
"      Hill JM, McGuire MH, Crosby LA. Closed treatment of displaced middle-third fractures of the clavicle gives poor results. J Bone Joint Surg Br 1997; 79:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/15\">",
"      Denard PJ, Koval KJ, Cantu RV, Weinstein JN. Management of midshaft clavicle fractures in adults. Am J Orthop (Belle Mead NJ) 2005; 34:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/16\">",
"      Nowak J, Holgersson M, Larsson S. Sequelae from clavicular fractures are common: a prospective study of 222 patients. Acta Orthop 2005; 76:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/17\">",
"      McKee RC, Whelan DB, Schemitsch EH, McKee MD. Operative versus nonoperative care of displaced midshaft clavicular fractures: a meta-analysis of randomized clinical trials. J Bone Joint Surg Am 2012; 94:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/18\">",
"      Zlowodzki M, Zelle BA, Cole PA, et al. Treatment of acute midshaft clavicle fractures: systematic review of 2144 fractures: on behalf of the Evidence-Based Orthopaedic Trauma Working Group. J Orthop Trauma 2005; 19:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/19\">",
"      Lazarides S, Zafiropoulos G. Conservative treatment of fractures at the middle third of the clavicle: the relevance of shortening and clinical outcome. J Shoulder Elbow Surg 2006; 15:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/20\">",
"      Nordqvist A, Petersson CJ, Redlund-Johnell I. Mid-clavicle fractures in adults: end result study after conservative treatment. J Orthop Trauma 1998; 12:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/21\">",
"      Andersen K, Jensen PO, Lauritzen J. Treatment of clavicular fractures. Figure-of-eight bandage versus a simple sling. Acta Orthop Scand 1987; 58:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/22\">",
"      McKee MD, Wild LM, Schemitsch EH. Midshaft malunions of the clavicle. J Bone Joint Surg Am 2003; 85-A:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/23\">",
"      Housner JA, Kuhn JE. Clavicle fractures: individualizing treatment for fracture type. Phys Sportsmed 2003; 31:30.",
"     </a>",
"    </li>",
"    <li>",
"     Clavicular fractures in children. Wheeless' Textbook of Orthopedics. www.wheelessonline.com/ortho/clavicle_fractures (Accessed on December 12, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/25\">",
"      Goldberg JA, Bruce WJ, Sonnabend DH, Walsh WR. Type 2 fractures of the distal clavicle: a new surgical technique. J Shoulder Elbow Surg 1997; 6:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/26\">",
"      Mall JW, Jacobi CA, Philipp AW, Peter FJ. Surgical treatment of fractures of the distal clavicle with polydioxanone suture tension band wiring: an alternative osteosynthesis. J Orthop Sci 2002; 7:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/27\">",
"      Kao FC, Chao EK, Chen CH, et al. Treatment of distal clavicle fracture using Kirschner wires and tension-band wires. J Trauma 2001; 51:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/28\">",
"      Chen CH, Chen WJ, Shih CH. Surgical treatment for distal clavicle fracture with coracoclavicular ligament disruption. J Trauma 2002; 52:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/29\">",
"      Levy O. Simple, minimally invasive surgical technique for treatment of type 2 fractures of the distal clavicle. J Shoulder Elbow Surg 2003; 12:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/30\">",
"      Deafenbaugh MK, Dugdale TW, Staeheli JW, Nielsen R. Nonoperative treatment of Neer type II distal clavicle fractures: a prospective study. Contemp Orthop 1990; 20:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/31\">",
"      Anderson K. Evaluation and treatment of distal clavicle fractures. Clin Sports Med 2003; 22:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/32\">",
"      Rokito, AS, Zuckerman, JD, Shaari, JM, et al. A comparison of nonoperative and operative treatment of type II distal clavicle fractures. Bull Hosp Jt Dis 2002-2003; 61:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/33\">",
"      Nordqvist A, Petersson C, Redlund-Johnell I. The natural course of lateral clavicle fracture. 15 (11-21) year follow-up of 110 cases. Acta Orthop Scand 1993; 64:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/34\">",
"      Abbot AE, Hannafin JA. Stress fracture of the clavicle in a female lightweight rower. A case report and review of the literature. Am J Sports Med 2001; 29:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/35\">",
"      Fallon KE, Fricker PA. Stress fracture of the clavicle in a young female gymnast. Br J Sports Med 2001; 35:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/36\">",
"      Peebles CR, Sulkin T, Sampson MA. 'Cable-maker's clavicle': stress fracture of the medial clavicle. Skeletal Radiol 2000; 29:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/37\">",
"      Yamada K, Sugiura H, Suzuki Y. Stress fracture of the medial clavicle secondary to nervous tic. Skeletal Radiol 2004; 33:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/38\">",
"      Brinker MR, Simon RG. Pseudo-dislocation of the sternoclavicular joint. J Orthop Trauma 1999; 13:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12985/abstract/39\">",
"      Lehnert M, Maier B, Jakob H, et al. Fracture and retrosternal dislocation of the medial clavicle in a 12-year-old child--case report, options for diagnosis, and treatment in children. J Pediatr Surg 2005; 40:e1.",
"     </a>",
"    </li>",
"    <li>",
"     Craig, EV. Fractures of the clavicle. In: The Shoulder, Rockwood, CA, Matson, FA (Eds), WB Saunders, Philadelphia 1998. p.428.",
"    </li>",
"    <li>",
"     Ring, D, Jupiter, JB, Miller, ME, et al. Part II, Fractures of the clavicle. In: Skeletal Trauma: Fractures, Dislocations, Ligamentous Injuries, II, Browner, BD, Jupiter, JB, Levine, AL, Trafton, PG (Eds), WB Saunders, Philadelphia 1998. p.1670.",
"    </li>",
"    <li>",
"     Garrick, JG, Webb, DR. Fractures of the proximal and middle thirds of the clavicle. In: Sports Injuries: Diagnosis and Management, 2nd ed, Garrick, JG, Webb, DR (Eds), WB Saunders, Philadelphia 1999. p.93.",
"    </li>",
"    <li>",
"     Schlegel, TF, Hawkins, RJ. Fractures of the shoulder girdle. In: Shoulder Injuries in the Athlete: Surgical Repair and Rehabilitation, Hawkins, RJ, Misamore, GW (Eds), Churchill Livingstone, New York 1996. p.219.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 231 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_43_12985=[""].join("\n");
var outline_f12_43_12985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      FRACTURES OF THE MIDDLE THIRD (MIDSHAFT) OF THE CLAVICLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical presentation and examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Indications for orthopedic referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initial nonoperative treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Follow-up care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pediatric considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      FRACTURES OF THE DISTAL THIRD OF THE CLAVICLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinical presentation and examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Indications for orthopedic referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Follow-up care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pediatric considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      FRACTURES OF THE PROXIMAL THIRD OF THE CLAVICLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Clinical presentation and examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Indications for referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Follow-up care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Pediatric considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      RETURN TO WORK OR SPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/231\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/231|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/14/44271\" title=\"diagnostic image 1\">",
"      Midshaft clavicle fracture with superior displacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/13/12511\" title=\"diagnostic image 2\">",
"      Midshaft clavicle fracture with shortening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/9/7327\" title=\"diagnostic image 3\">",
"      Comminuted clavicle fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/27/20913\" title=\"diagnostic image 4\">",
"      Cephalic view of clavicle fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/32/32271\" title=\"diagnostic image 5\">",
"      Clavicle fracture with nonunion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/0/1039\" title=\"diagnostic image 6\">",
"      Clavicle fracture with callus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/47/767\" title=\"diagnostic image 7\">",
"      Xray of distal clavicle fracture Type II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/51/5936\" title=\"diagnostic image 8\">",
"      Xray of distal clavicle fracture Type I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/231|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/41/24210\" title=\"figure 1\">",
"      Normal shoulder ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/51/38705\" title=\"figure 2\">",
"      Clavicle fracture displacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/10/22688\" title=\"figure 3\">",
"      Distal clavicle fracture type I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/0/7168\" title=\"figure 4\">",
"      Distal clavicle fracture type II A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/28/13760\" title=\"figure 5\">",
"      Distal clavicle fracture type II B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/41/16016\" title=\"figure 6\">",
"      Distal clavicle fracture type III",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/231|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/13/18640\" title=\"picture 1\">",
"      Figure 8 bandage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10663?source=related_link\">",
"      Acromioclavicular joint injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41752?source=related_link\">",
"      Intrapartum management and outcome of shoulder dystocia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=related_link\">",
"      Overview of stress fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39330?source=related_link\">",
"      Patient information: Clavicle fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=related_link\">",
"      Patient information: Fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=related_link\">",
"      Rotator cuff tendinopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_43_12986="Treatment of diabetic neuropathy";
var content_f12_43_12986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of diabetic neuropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/43/12986/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/43/12986/contributors\">",
"     Eva L Feldman, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/43/12986/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/43/12986/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/43/12986/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/43/12986/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/43/12986/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/43/12986/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/43/12986/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral and autonomic neuropathies are a major cause of morbidity in patients with diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diabetic polyneuropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8938?source=see_link\">",
"     \"Diabetic autonomic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of diabetic peripheral neuropathy will be reviewed here. There are three main elements in the treatment regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Glycemic control",
"     </li>",
"     <li>",
"      Foot care",
"     </li>",
"     <li>",
"      Treatment of pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLYCEMIC CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important treatment for the prevention of diabetic neuropathy is optimal glucose control. In the Diabetes Control and Complications Trial (DCCT), the occurrence of diabetic neuropathy was reduced by 60 percent over a 10-year period with rigorous blood glucose control in patients with type 1 diabetes (",
"    <a class=\"graphic graphic_figure graphicRef70914 graphicRef50952 \" href=\"UTD.htm?12/40/12943\">",
"     figure 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Similar findings were noted in the Stockholm Diabetes Intervention Study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/3\">",
"     3",
"    </a>",
"    ]. The effect of hyperglycemia on disease progression appears to be dose-dependent: in the Oslo Diabetes study each 1 percent rise in hemoglobin A1C (HbA1C) values was associated with a 1.3",
"    <span class=\"nowrap\">",
"     m/sec",
"    </span>",
"    slowing of nerve conduction at eight years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41928?source=see_link\">",
"     \"Pathogenesis and prevention of diabetic polyneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Established neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of glycemic control in established diabetic neuropathy is uncertain, but several small, mostly uncontrolled studies suggest that neuropathic symptoms may improve with intensive antidiabetic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This issue was better addressed in the DCCT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/2\">",
"     2",
"    </a>",
"    ]. After follow-up for five years, patients with possible or definite clinical neuropathy at baseline, treated with intensive glycemic control, had an increase in nerve conduction velocity (",
"    <a class=\"graphic graphic_figure graphicRef70945 \" href=\"UTD.htm?4/16/4367\">",
"     figure 2",
"    </a>",
"    ). Whether this effect results in a reduced rate of progression of clinical neuropathy is not known.",
"   </p>",
"   <p>",
"    A practice statement issued by the American Diabetes Association in 2005 recommended that the first step in the management of patients with symptomatic diabetic polyneuropathy should be to aim for stable and optimal glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FOOT CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;We combine good glucose control with foot care. On a daily basis, patients need to inspect their feet for the presence of dry or cracking skin, fissures, plantar callus formation, and signs of early infection between the toes and around the toe nails. Regular foot examinations by the physician to detect early neuropathy are also an essential component of the treatment of diabetic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=see_link\">",
"     \"Evaluation of the diabetic foot\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once a patient has diabetic neuropathy, foot care is even more important to prevent ulceration, infection, and amputation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=see_link\">",
"     \"Management of diabetic foot lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PAINFUL DIABETIC NEUROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a small fraction of patients with diabetic polyneuropathy have painful symptoms. Patients with painful diabetic neuropathy should be treated with a systematic, stepwise approach [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/9\">",
"     9",
"    </a>",
"    ]. Before initiating therapy, it is important to confirm that the pain is due to neuropathy. The diagnosis of diabetic polyneuropathy is reviewed here briefly and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diabetic polyneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The onset of severe pain in the feet and lower limbs can be very distressing and disabling. A disc lesion should be considered if the pain has developed in relation to recent trauma or its onset is abrupt. In addition, pain due to disc disease is more often unilateral than pain related to peripheral neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=see_link\">",
"     \"Approach to the diagnosis and evaluation of low back pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of these features, the differential diagnosis is neuropathy or peripheral vascular disease. The physical examination may be helpful (decreased sensation or loss of deep tendon reflexes), but these signs of neuropathy do not necessarily mean that the pain is due to the neuropathy. Several clues that the patient has neuropathic pain are the location of pain (feet more than calves), the quality of the pain, and the timing of pain (present at rest, improves with walking) (",
"    <a class=\"graphic graphic_table graphicRef72373 \" href=\"UTD.htm?23/17/23835\">",
"     table 1",
"    </a>",
"    ). Each of these features is different from those of the pain due to ischemic vascular disease.",
"   </p>",
"   <p>",
"    Although uncommon compared with symmetric diabetic polyneuropathy, there are several other types of acute painful diabetic neuropathy syndromes. These are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment-induced diabetic neuropathy (also called insulin neuritis) that presents in the setting of rapid glycemic control",
"     </li>",
"     <li>",
"      Diabetic neuropathy that occurs in the setting of unintended severe weight loss (diabetic neuropathic cachexia)",
"     </li>",
"     <li>",
"      Diabetic neuropathy that is seen with intentional weight loss (diabetic anorexia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, these conditions are characterized by severe neuropathic pain, autonomic dysfunction, and a reversible course that may last for many months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations and diagnosis of diabetic polyneuropathy\", section on 'Acute painful diabetic neuropathies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, diabetic amyotrophy typically occurs in patients with type 2 diabetes mellitus. The traditional features include the acute, asymmetric, focal onset of pain followed by weakness involving the proximal leg, with associated autonomic failure and weight loss. Progression occurs over months and is followed by partial recovery in most patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=see_link\">",
"     \"Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Spontaneous resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of painful diabetic polyneuropathy is established, the patient should be informed that the condition is sometimes self-limited. In a prospective study of 29 patients, for example, pain remitted within 12 months in 16 patients (55 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/10\">",
"     10",
"    </a>",
"    ]. Remission was more likely if the onset of symptoms had followed a sudden metabolic change (either an episode of diabetic ketoacidosis or occasionally an improvement in glycemic control), when the duration of diabetes was relatively short, or when marked weight loss preceded the onset of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms responsible for the resolution of pain are not understood. Proposed mechanisms include altered perception of pain, further deterioration of the nerve so that it no longer responds to stimulation (so that the patient is at even greater risk from trauma), or improvement in nerve function. As an example, a neuron may spontaneously fire and cause pain while it is being damaged or while it is recovering. Thus, in a patient who has poor glycemic control the nerves may be starved of nutrients, leading to acute but reversible nerve injury. On the other hand, a previously silent (anesthetic) nerve may recover during improved glycemic control, leading to spontaneous firing and the perception of pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PAIN CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatments that may be beneficial for painful diabetic neuropathy include a number of antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ) and anticonvulsants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    , sodium",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ) as well as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    cream,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    patch, alpha-lipoic acid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    topical spray, and transcutaneous electrical nerve stimulation. The supporting evidence for these treatments is reviewed in the sections that follow, as are guideline recommendations (see",
"    <a class=\"local\" href=\"#H12039744\">",
"     'Guidelines'",
"    </a>",
"    below) and our approach to treatment (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Choice of therapy'",
"    </a>",
"    below.). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H236124\">",
"    <span class=\"h2\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence from randomized controlled trials that tricyclic drugs (mainly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ) and the antidepressants",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    are beneficial for reducing pain associated with diabetic neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Tricyclic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several tricyclic antidepressant drugs (but not selective serotonin reuptake inhibitors) have been found in double-blind, randomized controlled trials to improve symptoms in patients with painful diabetic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Tricyclics may act by altering the central perception of pain. The therapeutic effect usually occurs sooner (within six weeks) and at lower doses than is typical when these drugs are given for the treatment of depression.",
"   </p>",
"   <p>",
"    These points are illustrated by the following trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a placebo-controlled, double-blind, randomized cross-over trial,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"       desipramine",
"      </a>",
"      were equally effective and superior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/12\">",
"       12",
"      </a>",
"      ]. The benefit of the tricyclic drugs was noted within two weeks and continued to increase at six weeks (",
"      <a class=\"graphic graphic_figure graphicRef55889 \" href=\"UTD.htm?13/19/13630\">",
"       figure 3",
"      </a>",
"      ). Desipramine had somewhat fewer side effects than amitriptyline, particularly dry mouth (",
"      <a class=\"graphic graphic_table graphicRef74923 \" href=\"UTD.htm?5/59/6076\">",
"       table 2",
"      </a>",
"      ). The average effective dose, titrated over six weeks to achieve control of symptoms, was 111",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for desipramine and 105",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for amitriptyline. There was no correlation between relief of pain, dosage, or plasma drug concentrations, suggesting that the clinical response and tolerability of side effects are the best guides to dose titration.",
"     </li>",
"     <li>",
"      A randomized, blinded cross-over trial of 58 adults with painful diabetic neuropathy that compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      (10 to 50 mg daily) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      (20 to 60 mg daily) given at bed time found a significant improvement in pain with both medications compared with pre-treatment baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/15\">",
"       15",
"      </a>",
"      ]. A good outcome, defined as a median pain score reduction of &gt;50 percent, was reported at a similar rate for amitriptyline and duloxetine (55 versus 59 percent), and the difference was not significant. Dry mouth was significantly more frequent with amitriptyline compared with duloxetine (55 versus 24 percent), while constipation was nonsignificantly more frequent with duloxetine (37 versus 17 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We use either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    in patients with severe pain. This class of drugs can be added to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    or anticonvulsants but not to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    . The starting dose of desipramine is 25 mg, taken at bedtime. The dose can be increased to a maximum of 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    over a few weeks.",
"   </p>",
"   <p>",
"    The choice of a specific drug may vary:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We frequently substitute",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      if anticholinergic side effects are a problem.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       Amitriptyline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      are both contraindicated in patients with cardiac disease. In these patients, we consult with the patient's cardiologist and give either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"       doxepin",
"      </a>",
"      , the least cardiotoxic tricyclic antidepressant, or antidepressant drugs unrelated to the tricyclic family such",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Common side-effects of tricyclic antidepressants include dry mouth and somnolence. We suggest initiating tricyclic therapy with a dose at bedtime. Urinary retention may occur, especially in men with enlarged prostates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Duloxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review published in 2009 concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    , a dual serotonin and norepinephrine reuptake inhibitor, is effective for the treatment of painful diabetic polyneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/16\">",
"     16",
"    </a>",
"    ]. Another systematic review published in 2011 that evaluated the same evidence concluded that duloxetine is probably effective in lessening the pain of diabetic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/17\">",
"     17",
"    </a>",
"    ]. The benefit of duloxetine was established in three 12-week randomized, blinded, controlled trials involving 1102 subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. In these trials, pain improvement occurred significantly more frequently with duloxetine 60 or 120 mg daily than with placebo (47 and 48 percent, versus 29 percent with placebo). Pain improvement was noted as early as the first week of treatment and continued for the duration of the studies. Duloxetine showed rapid onset of action and sustained benefit, and it was also effective in relieving pain at night. The 120 mg daily dose was not as well tolerated as 60 mg daily, although both were beneficial.",
"   </p>",
"   <p>",
"    While",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    was more effective than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/16\">",
"     16",
"    </a>",
"    ], all three trials were of relatively short duration, and the long-term effectiveness and safety of duloxetine is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/21\">",
"     21",
"    </a>",
"    ]. Furthermore, in clinical trials evaluating painful diabetic polyneuropathy, duloxetine treatment resulted in modest increases in fasting plasma glucose [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/22\">",
"     22",
"    </a>",
"    ]. Although comparative trials are few,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    appears to be as effective as duloxetine for the treatment of painful diabetic neuropathy, and is less expensive. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Tricyclic drugs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The most common reported side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    were nausea, somnolence, dizziness, decreased appetite, and constipation. Hot flashes and erectile dysfunction were also reported infrequently.",
"   </p>",
"   <p>",
"    Because nausea is common, patients are encouraged to take the drug on a full stomach.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     Duloxetine",
"    </a>",
"    should not be taken with other serotonin or norepinephrine uptake inhibitors but can be combined with anticonvulsant therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H236306\">",
"    <span class=\"h3\">",
"     Venlafaxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized controlled trial, extended-release (ER)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    was evaluated in 244 patients with painful diabetic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/23\">",
"     23",
"    </a>",
"    ]. At six weeks, treatment with ER venlafaxine at higher (150 to 225 mg daily) but not lower (75 mg daily) doses was associated with significant benefit in the primary outcome measures of pain intensity and pain relief compared with placebo. The strength of this finding is limited by the short duration of this trial. Nausea and somnolence were the most common side effects of venlafaxine, and blood pressure and cardiac rhythm changes occurred more often with venlafaxine treatment than with placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both newer (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ) and older (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ) anticonvulsants may be useful for treating painful DPN. The utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H235925\">",
"    <span class=\"h3\">",
"     Pregabalin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     Pregabalin",
"    </a>",
"    is an alpha2-delta ligand that is structurally related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    but without known activity at GABA or benzodiazepine receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/24\">",
"     24",
"    </a>",
"    ]. It appears to act as a presynaptic inhibitor of the release of excitatory neurotransmitters including glutamate, substance P, and calcitonin gene-related peptide (CGRP) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    for the treatment of painful diabetic neuropathy was evaluated in a pooled analysis of seven randomized clinical trials, of 5 to 13 weeks duration, with a total of 1510 patients in the intention-to-treat population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/27\">",
"     27",
"    </a>",
"    ]. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with placebo,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      treatment at total daily doses of 150, 300, and 600 mg resulted in a statistically significant reduction in the mean pain score, the primary end point of all included studies. The median time to a sustained one point improvement in pain score for pregabalin (at 150 mg, 300 mg, and 600 mg) and placebo was 13, 5, 4, and 60 days, respectively.",
"     </li>",
"     <li>",
"      With higher doses, there was a clear dose-related increase in effectiveness, and an increase in the incidence of most adverse events.",
"     </li>",
"     <li>",
"      The most common adverse events were dizziness, somnolence, and peripheral edema. The incidence of clinically meaningful weight gain (defined as a &ge;7 percent weight increase from baseline to end point) was significantly higher for patients assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      than for those assigned to placebo (2.0 to 3.9 percent versus 0.7 percent), but weight gain did not affect diabetes control.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     Pregabalin",
"    </a>",
"    is started at 50 mg twice a day (total 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and is then slowly increased to 150 mg two times a day (total 300",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    the maximum dose approved by the FDA for diabetes-associated neuropathic pain) over a week or more. It can also be administered 100 mg three times a day.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     Pregabalin",
"    </a>",
"    can cause a number of side effects, including dizziness, vertigo, incoordination, ataxia, diplopia, blurred vision, sedation, and confusion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/28\">",
"     28",
"    </a>",
"    ]. It may be habit forming and is classified as a Schedule V drug in the United States. It is generally held that more clinical experience with the drug will delineate if its efficacy outweighs its potential habit forming classification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Gabapentin",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is conflicting evidence regarding the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    for the treatment of painful diabetic neuropathy. In one published randomized, double-blind trial that evaluated 165 patients with pain attributed to diabetic neuropathy, gabapentin reduced pain and sleep interference and improved mood and quality of life compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/29\">",
"     29",
"    </a>",
"    ]. Although the benefit of gabapentin was statistically significant, the effect size was small [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/17\">",
"     17",
"    </a>",
"    ]. A smaller randomized trial found that gabapentin was",
"    <strong>",
"     not",
"    </strong>",
"    superior to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/30\">",
"     30",
"    </a>",
"    ]. Furthermore, one author (DM) of this topic is aware of three unpublished randomized controlled trials suggesting that gabapentin is worse or no better than placebo for the treatment of painful diabetic neuropathy, and a review of published and unpublished trials calls into question the efficacy of gabapentin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/31\">",
"     31",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Given that the available evidence is conflicting and incomplete, the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    for the treatment of painful diabetic neuropathy is controversial. Some experts no longer use gabapentin for painful diabetic neuropathy, believing it to be no better than placebo. However, the clinical experience of other experts suggests that gabapentin has a role. Typical starting doses for gabapentin are 300 to 600 mg three times daily; the drug can be titrated slowly up to 900 mg four times daily. The major side effects of gabapentin are somnolence, dizziness and ataxia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Other anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valproic acid (500 to 1200 mg daily) was effective for reducing pain in diabetic neuropathy in two small placebo-controlled trials from a single center [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. However, it should not be used to treat diabetic neuropathy in women of childbearing potential because of teratogenic effects. Carbamazepine may also have some benefit, but it has not been evaluated in modern randomized trials for the treatment of painful diabetic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The evidence regarding benefit of topiramate for painful diabetic polyneuropathy is equivocal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Capsaicin cream",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     Capsaicin",
"    </a>",
"    is a naturally occurring component of many hot peppers and causes analgesia through local depletion of substance P. It is available in a cream for topical application. In randomized trials in patients with painful diabetic neuropathy, capsaicin has been associated with modest but statistically significant improvement in pain compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/17,38-40\">",
"     17,38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    (0.075 percent applied topically four times daily) for patients with symptomatic painful diabetic polyneuropathy who are refractory to or intolerant of antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ) or anticonvulsants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ) discussed above. Local burning and skin irritation can occur, but this becomes less of a problem with continued use. Nevertheless, many patients are unable to tolerate the local burning pain, which is exacerbated by contact with warm water and hot weather [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Anesthetic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review published in 2011 concluded that the evidence for the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    is conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/17\">",
"     17",
"    </a>",
"    ]. The highest-quality trial evaluated found no significant benefit of mexiletine compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/41\">",
"     41",
"    </a>",
"    ]. However, other trials suggested benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An open-label trial found that application of up to four",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    patches (5 percent) for up to 18 hours per day significantly improved pain and quality of life ratings in 56 patients with painful diabetic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/44\">",
"     44",
"    </a>",
"    ]. A randomized trial is necessary to confirm these results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Alpha-lipoic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the mechanisms implicated in the pathogenesis of diabetic neuropathy is increased oxidative stress. As a result, antioxidants have been studied for their potential to diminish oxidative stress, improve the underlying pathophysiology of neuropathy, and reduce pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41928?source=see_link\">",
"     \"Pathogenesis and prevention of diabetic polyneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alpha-lipoic acid (ALA), a potent antioxidant, has been associated with benefit for symptomatic diabetic neuropathy in several prospective, placebo-controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. In the SYDNEY 1 trial, daily intravenous ALA for three weeks was associated with reduced pain, paresthesia, and numbness [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the SYDNEY 2 trial, 181 patients with diabetes and symptomatic distal symmetric polyneuropathy were randomly assigned to one of three doses of orally administered ALA (600, 1200, or 1800 mg daily) or to placebo for five weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/48\">",
"     48",
"    </a>",
"    ]. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All three doses of oral ALA treatment were associated with a statistically significant reduction in the primary outcome measure, the neuropathy total symptom score (a summation of stabbing pain, burning pain, paresthesia, and asleep numbness), compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/48\">",
"       48",
"      </a>",
"      ]. The benefit of ALA did not differ by dose.",
"     </li>",
"     <li>",
"      A clinically meaningful response, defined as &ge;50 percent reduction in neuropathic symptoms, was observed in 50 to 62 percent of patients treated with ALA versus 26 percent with placebo, a difference that was statistically significant.",
"     </li>",
"     <li>",
"      The optimal dose of ALA was 600 mg once daily, as higher doses were limited by increasing adverse events (nausea, vomiting, and vertigo) without increasing efficacy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The strength of these findings is limited by the short duration of this trial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/48\">",
"     48",
"    </a>",
"    ]. There are no long-term studies that assess the affect of alpha-lipoic acid on progression of neuropathy.",
"   </p>",
"   <p>",
"    However, based upon these data, we suggest treatment with oral ALA 600 mg once daily for patients with symptomatic painful diabetic polyneuropathy who are refractory to or intolerant of antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ) or anticonvulsants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ) that have been established as beneficial for this condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of opioids have been studied for the treatment of painful diabetic neuropathy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"       Dextromethorphan",
"      </a>",
"      , a weak sigma opioid receptor agonist and a NMDA receptor antagonist, was moderately beneficial compared with placebo in two small trials for reducing pain in patients with diabetic neuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In two small randomized, double-blind trials",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    , at an average dose of 210",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    was more effective than placebo for relieving pain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The most frequent adverse effects were nausea, constipation, headache, and somnolence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Controlled release (CR)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      at a daily dose of 10 to 60 mg appears be effective and safe for the treatment of painful diabetic polyneuropathy, as shown in two randomized clinical trials [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. In the larger of these trials involving 159 patients, oxycodone CR at an average dose of 37 mg daily (range 10 to 99 mg daily) provided more pain relief than placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The trials supporting the efficacy of opioids such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    CR are all limited by short-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/51-55\">",
"     51-55",
"    </a>",
"    ]. A 2009 systematic review of opioids for chronic noncancer pain found a paucity of evidence regarding the long-term effectiveness and risks of such treatment, including the potential for opioid abuse, addiction, and overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/55\">",
"     55",
"    </a>",
"    ]. In a subsequent cohort study of over 9900 patients prescribed long-term opioid therapy for non-malignant pain, the use of higher-dose regimens was associated with an increased risk of opioid overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/56\">",
"     56",
"    </a>",
"    ]. Because of these issues, some experts have stopped using opioids altogether for the treatment of painful diabetic neuropathy. We suggest",
"    <strong>",
"     not",
"    </strong>",
"    using opioids for the treatment of painful diabetic neuropathy because of the lack of evidence regarding long-term effectiveness, and because of the potential for tolerance, addiction, and overdose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from small trials suggest that the treatment of neuropathic pain with combinations of drugs from different medication classes is modestly more effective than monotherapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single-center randomized trial of 44 patients with neuropathic pain (a majority with diabetic polyneuropathy),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      was more effective than either agent alone for reducing the mean intensity of pain during week four of treatment at the maximum tolerated daily dose (mean, gabapentin 1705 mg and morphine 34 mg in combination) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/57\">",
"       57",
"      </a>",
"      ]. Constipation, sedation, and dry mouth were the most frequent side effects of the combination therapy.",
"     </li>",
"     <li>",
"      A similar single center randomized trial of 47 patients (most with diabetic polyneuropathy) found that the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      was more effective than either agent alone for reducing the mean intensity of daily pain during week four of treatment at the maximum tolerated daily dose (mean, nortriptyline 50 mg and gabapentin 2180 mg in combination) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both reports, the benefit of combination treatment was small but statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Electrical nerve stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are limited, a 2010 statement from the American Academy of Neurology (AAN) assessing the use of TENS for pain in neurologic disorders concluded that TENS is probably effective for reducing pain from diabetic polyneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/59\">",
"     59",
"    </a>",
"    ], based upon the following evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial assigned 31 patients with chronic painful diabetic neuropathy to either TENS or sham treatment to the legs for 30 minutes daily for four weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/60\">",
"       60",
"      </a>",
"      ]. Symptomatic improvement (of at least one grade on a unique zero to five scale) occurred in 15 of 18 patients (83 percent) with TENS treatment, compared with five of 13 patients (38 percent) who received sham treatment (odds ratio 6, 95% CI 1.1-33.4) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another trial evaluated 19 patients with mild to moderate symptomatic diabetic polyneuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/61\">",
"       61",
"      </a>",
"      ]. Compared with sham treatment, active treatment with TENS led to a statistically significant reduction in total symptom score at six and twelve weeks. In addition, TENS therapy was associated with a statistically significant but modest improvement in pain on the visual analog scale at six weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent 2011 guideline from the AAN evaluating the treatment of painful diabetic neuropathy concluded that",
"    <strong>",
"     percutaneous",
"    </strong>",
"    electrical nerve stimulation is probably effective [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/17\">",
"     17",
"    </a>",
"    ], based upon three small trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. However, the percutaneous techniques evaluated in the 2011 AAN guideline are not widely available in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other approaches have been tried in patients with painful diabetic neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Acetyl-L-carnitine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acetyl-L-carnitine (ALC), the acetylated ester of the amino acid",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    , has been evaluated in patients with diabetic peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/65\">",
"     65",
"    </a>",
"    ]. In data from two randomized controlled trials of identical design, an intention to treat analysis of 1257 patients with diabetic polyneuropathy found that ALC 1000 mg (but not 500 mg) three times daily compared with placebo was associated with significant improvement in pain scores in one of the studies and in the combined cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/66\">",
"     66",
"    </a>",
"    ]. The benefit of ALC requires confirmation, particularly since significant improvement was not seen in both trials or at the lower dose of ALC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Isosorbide",
"    </span>",
"    &nbsp;&mdash;&nbsp;A placebo-controlled pilot study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    topical spray in 22 diabetic patients reported a significant reduction in overall neuropathic pain and burning sensation in the treatment group [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) are effective in patients with musculoskeletal or joint abnormalities secondary to long-standing neuropathy; the joint deformities may actually be the primary source of pain (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22358?source=see_link\">",
"     \"Musculoskeletal complications in diabetes mellitus\"",
"    </a>",
"    ). Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (600 mg four times daily) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    (200 mg twice daily) can lead to substantial pain relief in patients with diabetic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a theoretical concern that NSAIDs may impair nerve circulation and worsen nerve injury due to inhibition of prostacyclin synthesis. Cautious use of this class of drugs is warranted until this possibility is fully evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12039744\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Neurology (AAN) performed a systematic review and published guidelines in 2011 for the treatment of painful diabetic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/17\">",
"     17",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       Pregabalin",
"      </a>",
"      (300 to 600 mg daily) was regarded as",
"      <strong>",
"       effective",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of treatments were regarded as",
"      <strong>",
"       probably effective",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/17\">",
"       17",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      , 900 to 3600 mg daily",
"     </li>",
"     <li>",
"      Sodium",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , 500 to 1200 mg daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       Amitriptyline",
"      </a>",
"      , 25 to 100 mg daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       Duloxetine",
"      </a>",
"      , 60 to 120 mg daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       Venlafaxine",
"      </a>",
"      , 75 to 225 mg daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"       Dextromethorphan",
"      </a>",
"      , 400 mg daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       Morphine",
"      </a>",
"      sulphate, titrated to 120 mg daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"       Oxycodone",
"      </a>",
"      , mean 37 mg daily, maximum 120 mg daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"       Tramadol",
"      </a>",
"      , 210 mg daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"       Capsaicin",
"      </a>",
"      , 0.075 percent four times daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"       Isosorbide dinitrate",
"      </a>",
"      spray",
"     </li>",
"     <li>",
"      Percutaneous electrical nerve stimulation for three to four weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      patch was regarded as",
"      <strong>",
"       possibly effective",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/17\">",
"       17",
"      </a>",
"      ]",
"      <strong>",
"       .",
"      </strong>",
"     </li>",
"     <li>",
"      Treatments regarded as",
"      <strong>",
"       probably not effective",
"      </strong>",
"      by the AAN were",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/19/35125?source=see_link\">",
"       lacosamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"       mexiletine",
"      </a>",
"      , magnetic field treatment, low-intensity laser therapy, and Reiki therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A management algorithm outlined by a statement published in 2005 from the American Diabetes Association (ADA) recommended treatment in sequential steps ordered as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exclude nondiabetic etiologies",
"     </li>",
"     <li>",
"      Stabilize glycemic control (insulin not always required in type 2 diabetes)",
"     </li>",
"     <li>",
"      Tricyclic drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      25 to 150 mg before bed)",
"     </li>",
"     <li>",
"      Anticonvulsants (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      , typical dose 1.8",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"     </li>",
"     <li>",
"      Opioid or opioid-like drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"      or controlled release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Consider pain clinic referral",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ADA statement noted that nonpharmacologic, topical, or physical therapies might be useful at any stage. These measures include acupuncture,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    , glyceryl trinitrate spray or patches, and other therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/9,69\">",
"     9,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest using one of the antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ) or anticonvulsants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ) discussed above as initial therapy for patients with painful diabetic neuropathy. The available evidence suggests that these agents have similar modest benefit, though few high-quality comparative trials have been done [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/15,70,71\">",
"     15,70,71",
"    </a>",
"    ]. Among these options, we prefer to start with amitriptyline, particularly in younger healthier patients, because of its effectiveness and low cost. Patients who fail to improve with a reasonable trial of one of these agents can be switched to monotherapy with another agent. (See",
"    <a class=\"local\" href=\"#H236124\">",
"     'Antidepressants'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Anticonvulsants'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients who do not improve on one drug, we suggest combination therapy employing two drugs from different medication classes as the next step in the treatment paradigm. For patients who are unable to tolerate any of these drugs, alternative treatments include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    cream,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    patch, alpha-lipoic acid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    topical spray, and transcutaneous electrical nerve stimulation. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Capsaicin cream'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Anesthetic drugs'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17\">",
"     'Alpha-lipoic acid'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'Opioids'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H19\">",
"     'Combination therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20\">",
"     'Electrical nerve stimulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of opioids for chronic nonmalignant pain is controversial. We suggest",
"    <strong>",
"     not",
"    </strong>",
"    using opioids for the treatment of painful diabetic neuropathy because of the lack of evidence regarding long-term effectiveness, and because of the potential for opioid tolerance, addiction, and overdose. However, other experts believe that opioids have a role in the management of painful diabetic neuropathy despite these concerns [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Opioids'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The treatment options and suggested doses are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef67254 \" href=\"UTD.htm?30/36/31307\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The role of glycemic control in established diabetic neuropathy is uncertain. However, strict glycemic control is associated with a reduced risk of microvascular complications in patients with type 2 diabetes, and intensive therapy may reduce the risk of macrovascular complications in such patients. In addition, tight glycemic control is associated with a reduction in microvascular and macrovascular complications for patients with type 1 diabetes. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     NONGLYCEMIC MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multifactorial risk factor reduction and aldose reductase inhibitors are potential strategies for treating diabetic neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Multifactorial risk factor reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential efficacy of intensive combined therapy in patients with type 2 diabetes and microalbuminuria was examined in the Steno type 2 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/72\">",
"     72",
"    </a>",
"    ]. In this prospective study, 160 patients were randomly assigned to standard or multifactorial intensive therapy. The intensive regimen consisted of behavioral therapy (including advice concerning diet, exercise, and smoking cessation) and pharmacologic intervention (consisting of the administration of multiple agents to attain several aggressive therapeutic goals) (",
"    <a class=\"graphic graphic_table graphicRef69810 \" href=\"UTD.htm?5/1/5148\">",
"     table 4",
"    </a>",
"    ). Diabetic autonomic and peripheral neuropathy were present at baseline in 28 and 34 percent, respectively.",
"   </p>",
"   <p>",
"    At a mean follow-up of 7.8 years, there was a significantly lower rate of progression of autonomic neuropathy in the intensive therapy group (30 versus 54 percent, relative risk 0.37), but no slowing of progression of peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The details of the protocol and overall results of this study are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Multifactorial risk factor reduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Aldose reductase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to lowering blood glucose concentrations, another potential approach is to minimize the toxicity of hyperglycemia. To the degree that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    accumulation may play a role in diabetic neuropathy, use of an aldose reductase inhibitor to prevent sorbitol formation might be beneficial.",
"   </p>",
"   <p>",
"    In the available studies of this unapproved class of medications, aldose reductase inhibitors have produced inconsistent benefits in diabetic neuropathy. The evidence is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/44/13000?source=see_link&amp;anchor=H8#H8\">",
"     \"Aldose reductase inhibitors in the prevention of diabetic complications\", section on 'Neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Surgical decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical decompression of multiple peripheral nerves (called the Dellon procedure) is an alternative, controversial method for treating diabetic polyneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/73\">",
"     73",
"    </a>",
"    ]. The purported rationale for surgical decompression is based on the notion that the metabolic stress of diabetes renders peripheral nerves susceptible to compressive injury at sites of potential nerve entrapment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/74-76\">",
"     74-76",
"    </a>",
"    ], and that compressive injury of multiple peripheral nerves is what leads to symptoms in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there are no adequately designed trials to support the use of surgical decompression of multiple peripheral nerves as a treatment for symptomatic diabetic polyneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/43/12986/abstract/74\">",
"     74",
"    </a>",
"    ]. Therefore, this treatment is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20208?source=see_link\">",
"       \"Patient information: Nerve damage caused by diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/42/8867?source=see_link\">",
"       \"Patient information: Neuropathic pain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/5/21587?source=see_link\">",
"       \"Patient information: Diabetic neuropathy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H237049\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The role of glycemic control in established diabetic neuropathy is uncertain, but several small, mostly uncontrolled studies suggest that neuropathic symptoms may improve with intensive antidiabetic therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Established neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with diabetic neuropathy, foot care is important to prevent ulceration, infection, and amputation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Foot care'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=see_link\">",
"       \"Management of diabetic foot lesions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Only a small fraction of patients with diabetic polyneuropathy have painful symptoms. In addition, the pain associated with diabetic polyneuropathy is often self-limited; evidence from a small prospective study suggests that resolution occurs over 12 months in approximately one-half of patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Painful diabetic neuropathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Spontaneous resolution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with painful diabetic neuropathy, we suggest initial therapy using either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Among these options, we prefer to start with amitriptyline, particularly in younger healthier patients, because of its effectiveness and low cost. For patients who do not improve on one drug, we suggest combination therapy employing two drugs from different medication classes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients who are unable to tolerate any of these drugs, alternative treatments include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      cream,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      patch, alpha-lipoic acid,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"       isosorbide dinitrate",
"      </a>",
"      topical spray, and transcutaneous electrical nerve stimulation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pain control'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of opioids for chronic nonmalignant pain is controversial. We suggest",
"      <strong>",
"       not",
"      </strong>",
"      using opioids for the treatment of painful diabetic neuropathy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Opioids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonglycemic interventions (eg, multifactorial risk factor reduction and aldose reductase inhibitors) are under investigation for treating or preventing diabetic neuropathy. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Nonglycemic measures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/1\">",
"      The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1995; 122:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/2\">",
"      Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995; 38:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/3\">",
"      Reichard P, Berglund B, Britz A, et al. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 1991; 230:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/4\">",
"      Amthor KF, Dahl-J&oslash;rgensen K, Berg TJ, et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: the Oslo Study. Diabetologia 1994; 37:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/5\">",
"      Boulton AJ, Drury J, Clarke B, Ward JD. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 1982; 5:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/6\">",
"      Greene DA, Brown MJ, Braunstein SN, et al. Comparison of clinical couse and sequential electrophysiological tests in diabetics with symptomatic polyneuropathy and its implications for clinical trials. Diabetes 1981; 30:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/7\">",
"      Tolaymat A, Roque JL, Russo LS Jr. Improvement of diabetic peripheral neuropathy with the portable insulin infusion pump. South Med J 1982; 75:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/8\">",
"      White NH, Waltman SR, Krupin T, Santiago JV. Reversal of neuropathic and gastrointestinal complications related to diabetes mellitus in adolescents with improved metabolic control. J Pediatr 1981; 99:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/9\">",
"      Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/10\">",
"      Young RJ, Ewing DJ, Clarke BF. Chronic and remitting painful diabetic polyneuropathy. Correlations with clinical features and subsequent changes in neurophysiology. Diabetes Care 1988; 11:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/11\">",
"      Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/12\">",
"      Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/13\">",
"      Kvinesdal B, Molin J, Fr&oslash;land A, Gram LF. Imipramine treatment of painful diabetic neuropathy. JAMA 1984; 251:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/14\">",
"      Vrethem M, Boivie J, Arnqvist H, et al. A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain 1997; 13:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/15\">",
"      Kaur H, Hota D, Bhansali A, et al. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. Diabetes Care 2011; 34:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/16\">",
"      Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev 2009; :CD007115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/17\">",
"      Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011; 76:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/18\">",
"      Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/19\">",
"      Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/20\">",
"      Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/21\">",
"      Duloxetine (Cymbalta) for diabetic neuropathic pain. Med Lett Drugs Ther 2005; 47:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/22\">",
"      Hardy T, Sachson R, Shen S, et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007; 30:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/23\">",
"      Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/24\">",
"      Bryans JS, Wustrow DJ. 3-substituted GABA analogs with central nervous system activity: a review. Med Res Rev 1999; 19:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/25\">",
"      Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000; 280:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/26\">",
"      Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003; 105:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/27\">",
"      Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008; 31:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/28\">",
"      Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011; 52:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/29\">",
"      Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/30\">",
"      Gorson KC, Schott C, Herman R, et al. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999; 66:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/31\">",
"      Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 2009; 361:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/32\">",
"      Kochar DK, Jain N, Agarwal RP, et al. Sodium valproate in the management of painful neuropathy in type 2 diabetes - a randomized placebo controlled study. Acta Neurol Scand 2002; 106:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/33\">",
"      Kochar DK, Rawat N, Agrawal RP, et al. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM 2004; 97:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/34\">",
"      Rull JA, Quibrera R, Gonz&aacute;lez-Mill&aacute;n H, Lozano Casta&ntilde;eda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia 1969; 5:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/35\">",
"      Chakrabarti AK, Samantaray SK. Diabetic peripheral neuropathy: nerve conduction studies before, during and after carbamazepine therapy. Aust N Z J Med 1976; 6:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/36\">",
"      Raskin P, Donofrio PD, Rosenthal NR, et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 2004; 63:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/37\">",
"      Thienel U, Neto W, Schwabe SK, et al. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand 2004; 110:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/38\">",
"      Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Capsaicin Study Group. Diabetes Care 1992; 15:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/39\">",
"      Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. The Capsaicin Study Group. Arch Intern Med 1991; 151:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/40\">",
"      Tandan R, Lewis GA, Krusinski PB, et al. Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care 1992; 15:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/41\">",
"      Wright JM, Oki JC, Graves L 3rd. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Ann Pharmacother 1997; 31:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/42\">",
"      Dejgard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988; 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/43\">",
"      Oskarsson P, Ljunggren JG, Lins PE. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group. Diabetes Care 1997; 20:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/44\">",
"      Barbano RL, Herrmann DN, Hart-Gouleau S, et al. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004; 61:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/45\">",
"      Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 1999; 16:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/46\">",
"      Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003; 26:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/47\">",
"      Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004; 21:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/48\">",
"      Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006; 29:2365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/49\">",
"      Sang CN, Booher S, Gilron I, et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002; 96:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/50\">",
"      Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997; 48:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/51\">",
"      Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/52\">",
"      Sindrup SH, Andersen G, Madsen C, et al. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999; 83:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/53\">",
"      Watson CP, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003; 105:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/54\">",
"      Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003; 60:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/55\">",
"      Chou R, Ballantyne JC, Fanciullo GJ, et al. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009; 10:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/56\">",
"      Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010; 152:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/57\">",
"      Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/58\">",
"      Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009; 374:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/59\">",
"      Dubinsky RM, Miyasaki J. Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010; 74:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/60\">",
"      Kumar D, Marshall HJ. Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation. Diabetes Care 1997; 20:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/61\">",
"      Forst T, Nguyen M, Forst S, et al. Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device. Diabetes Nutr Metab 2004; 17:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/62\">",
"      Hamza MA, White PF, Craig WF, et al. Percutaneous electrical nerve stimulation: a novel analgesic therapy for diabetic neuropathic pain. Diabetes Care 2000; 23:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/63\">",
"      Oyibo SO, Breislin K, Boulton AJ. Electrical stimulation therapy through stocking electrodes for painful diabetic neuropathy: a double blind, controlled crossover study. Diabet Med 2004; 21:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/64\">",
"      Bosi E, Conti M, Vermigli C, et al. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia 2005; 48:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/65\">",
"      Quatraro A, Roca P, Donzella C, et al. Acetyl-L-carnitine for symptomatic diabetic neuropathy. Diabetologia 1995; 38:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/66\">",
"      Sima AA, Calvani M, Mehra M, et al. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care 2005; 28:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/67\">",
"      Yuen KC, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care 2002; 25:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/68\">",
"      Cohen KL, Harris S. Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med 1987; 147:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/69\">",
"      Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004; 27:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/70\">",
"      Boyle J, Eriksson ME, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 2012; 35:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/71\">",
"      Boulton AJ. Is duloxetine more effective than amitriptyline for painful diabetic neuropathy? Curr Diab Rep 2011; 11:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/72\">",
"      Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/73\">",
"      Dellon AL. Treatment of symptomatic diabetic neuropathy by surgical decompression of multiple peripheral nerves. Plast Reconstr Surg 1992; 89:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/74\">",
"      Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Chaudhry V, Stevens JC, et al. Practice Advisory: utility of surgical decompression for treatment of diabetic neuropathy: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2006; 66:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/75\">",
"      Upton AR, McComas AJ. The double crush in nerve entrapment syndromes. Lancet 1973; 2:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/76\">",
"      Dellon AL, Mackinnon SE, Seiler WA 4th. Susceptibility of the diabetic nerve to chronic compression. Ann Plast Surg 1988; 20:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/43/12986/abstract/77\">",
"      Dellon AL, Mackinnon SE. Chronic nerve compression model for the double crush hypothesis. Ann Plast Surg 1991; 26:259.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5280 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-BFBE39938F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_43_12986=[""].join("\n");
var outline_f12_43_12986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H237049\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLYCEMIC CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Established neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FOOT CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PAINFUL DIABETIC NEUROPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Spontaneous resolution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PAIN CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H236124\">",
"      Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Tricyclic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Duloxetine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H236306\">",
"      - Venlafaxine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H235925\">",
"      - Pregabalin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Gabapentin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Other anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Capsaicin cream",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Anesthetic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Alpha-lipoic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Opioids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Electrical nerve stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Acetyl-L-carnitine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Isosorbide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12039744\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      NONGLYCEMIC MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Multifactorial risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Aldose reductase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Surgical decompression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H237049\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5280\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5280|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/56/39821\" title=\"figure 1A\">",
"      Neuropathy and glycemic control I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/8/3214\" title=\"figure 1B\">",
"      Neuropathy and glycemic control II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/16/4367\" title=\"figure 2\">",
"      Established neuropathy glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/19/13630\" title=\"figure 3\">",
"      Tricyclics for diabetic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5280|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/17/23835\" title=\"table 1\">",
"      Symptoms of diabetic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/59/6076\" title=\"table 2\">",
"      Side effects of drugs for diabetic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/36/31307\" title=\"table 3\">",
"      Treatment of painful diabetic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/1/5148\" title=\"table 4\">",
"      Treatment goals Steno type 2 study",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/44/13000?source=related_link\">",
"      Aldose reductase inhibitors in the prevention of diabetic complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=related_link\">",
"      Approach to the diagnosis and evaluation of low back pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=related_link\">",
"      Clinical manifestations and diagnosis of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20631?source=related_link\">",
"      Diabetic amyotrophy and idiopathic lumbosacral radiculoplexus neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8938?source=related_link\">",
"      Diabetic autonomic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=related_link\">",
"      Evaluation of the diabetic foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=related_link\">",
"      Management of diabetic foot lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22358?source=related_link\">",
"      Musculoskeletal complications in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41928?source=related_link\">",
"      Pathogenesis and prevention of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/5/21587?source=related_link\">",
"      Patient information: Diabetic neuropathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20208?source=related_link\">",
"      Patient information: Nerve damage caused by diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/42/8867?source=related_link\">",
"      Patient information: Neuropathic pain (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_43_12987="ASGE guideline anesthesiologist";
var content_f12_43_12987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guideline for anesthesiology assistance during gastrointestinal endoscopy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Anesthesiologist assistance may be considered in the following situations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Prolonged or therapeutic endoscopic procedure requiring deep sedation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anticipated intolerance to standard sedatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Increased risk for complication because of severe comorbidity (ASA class III or greater)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Increased risk for airway obstruction because of anatomic variant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The routine assistance of an anesthesiologist for average risk patients undergoing standard upper and lower endoscopic procedures is not warranted and is cost prohibitive.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Faigel DO, Baron TH, Goldstein JL, et al. Guidelines for the use of deep sedation and anesthesia for GI endoscopy. Gastrointest Endosc 2002; 56:613. Copyright &copy; 2002 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_43_12987=[""].join("\n");
var outline_f12_43_12987=null;
var title_f12_43_12988="Screening 13-item questionnaire for rTMS candidates";
var content_f12_43_12988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F85964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F85964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Screening 13-item questionnaire for rTMS candidates",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         1.",
"        </strong>",
"        Do you have epilepsy or have you ever had a convulsion or a seizure?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2.",
"        </strong>",
"        Have you ever had a fainting spell or syncope? If yes, please describe on which occasion(s).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         3.",
"        </strong>",
"        Have you ever had a head trauma that was diagnosed as a concussion or was associated with loss of consciousness?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         4.",
"        </strong>",
"        Do you have any hearing problems or ringing in your ears?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         5.",
"        </strong>",
"        Do you have cochlear implants?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         6.",
"        </strong>",
"        Are you pregnant or is there any chance that you might be?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         7.",
"        </strong>",
"        Do you have metal in the brain, scull, or elsewhere in your body (eg, splinters, fragments, clips, etc)? If so, specify the type of metal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         8.",
"        </strong>",
"        Do you have an implanted neurotransmitter (eg, DBS, epidural/subdural, VNS)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         9.",
"        </strong>",
"        Do you have a cardiac pacemaker or intracardiac lines?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         10.",
"        </strong>",
"        Do you have a medication infusion device?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         11.",
"        </strong>",
"        Are you taking any medications? (please list)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         12.",
"        </strong>",
"        Did you ever undergo TMS in the past? If so, were there any problems?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         13.",
"        </strong>",
"        Did you ever undergo MRI in the past? If so, were there any problems?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Screening questionnaire TMS: An update. Clin Neurophysiol 2011; 122:1686. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_43_12988=[""].join("\n");
var outline_f12_43_12988=null;
var title_f12_43_12989="Other diagnoses chest pain";
var content_f12_43_12989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Alternative diagnoses to cardiac ischemia for patients with chest pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Non-ischemic cardiovascular",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aortic dissection*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myocarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pericarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Chest wall",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cervical disc disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Costochondritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fibrositis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes zoster (before the rash)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neuropathic pain",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rib fracture",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sternoclavicular arthritis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Pulmonary",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pleuritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary embolus*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tension pneumothorax*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Psychiatric",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Affective disorders (eg, depression)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Anxiety disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hyperventilation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Panic disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Primary anxiety",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Somatiform disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Thought disorders (eg, fixed delusions)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Gastrointestinal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Biliary",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cholangitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cholecystitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Choledocholithiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Colic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Esophageal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Esophagitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Spasm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Reflux",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Rupture*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Peptic ulcer disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Nonperforating",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Perforating*",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Potentially life-threatening conditions.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: ACC/AHA/ACP Guidelines for the Management of Patients with Chronic Stable Angina. J Am Coll Cardiol 1999; 33:2092. Copyright &copy;1999 American College of Cardiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_43_12989=[""].join("\n");
var outline_f12_43_12989=null;
var title_f12_43_12990="Higher BNP level predicts adverse events after non ST ACS";
var content_f12_43_12990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Levels of brain natriuretic peptide predict cardiac events in patients with an acute coronary syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 315px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 2525 patients with a non-Q wave myocardial infarction or unstable angina, the incidence of death, new or progressive heart failure (HF), and new or recurrent myocardial infarction (MI) at 30 days and 10 months is higher in those with brain natriuretic peptide levels &gt;80 pg/mL (p &lt;0.005) compared to levels &le;80 pg/mL for each comparison.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from de Lemos JA, Morrow DA, Bently JH, et al. N Engl J Med 2001; 345:1014.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_43_12990=[""].join("\n");
var outline_f12_43_12990=null;
var title_f12_43_12991="Flecked retina Stargardts";
var content_f12_43_12991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F50625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F50625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flecked retina with Stargardt's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flecked retina in a 28 year old white woman with Stargardt's disease (fundus flavimaculatus, a juvenile onset mascular degeneration with a striking presentation of yellowish flecks surrounding the macula).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Eli Friedman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_43_12991=[""].join("\n");
var outline_f12_43_12991=null;
